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PHARMACOLOGIC AND GENETIC MANIPULATIONS OF ANGIOTENSIN 
SIGNALING IN THORACIC AORTIC DISEASE MODELS 
 
Andrew Milton Peters, B.S. 
 
Advisory Professor: Dianna M. Milewicz, M.D., Ph.D. 
 
Thoracic aortic aneurysms and dissections (TAAD) are a major cause of morbidity 
and mortality in patients. Many different risk factors have been associated TAAD, but 
hypertension is the largest risk factor. Subsets of TAAD patients have identifiable 
syndromic genetic diseases, yet a number of genetic non-syndromic patients have been 
identified. Infusion of angiotensin II into mouse models causes aortic disease through 
inflammation and fibrosis. An angiotensin type I receptor (AT1R) blocker (ARB) or an 
angiotensin converting enzyme (ACE) inhibitor (ACEi) can reverse aortic pathology in some 
mouse models. I set out to better understand the relationship between angiotensin and 
TAAD in our mouse models, and hypothesized that angiotensin II signaling through the 
AT1R contributes to thoracic aortic aneurysm formation in multiple model systems of 
disease, and that blocking related receptors in addition to the AT1R, such as the AT2R 
and Mas receptor, may have negative consequences. Previously identified genetic variants 
in the gene encoding smooth muscle alpha-actin, ACTA2, were modeled with Acta2-/- mice. 
vii 
 
I found that the ascending aorta and aortic root in these mice become significantly dilated 
over time. Acta2-/- mice are hypotensive, and increasing the blood pressure with a 
pharmaceutical and diet based regimen significantly accelerated and worsened the aortic 
phenotype. Treatment with losartan, an ARB, attenuated the aortic dilation, but captopril, 
an ACEi,  did not decrease aortic growth and worsened the disease. Transverse aortic 
constriction (TAC) was used to study the ascending aorta and aortic root in response to 
increased biomechanical forces. Losartan attenuated the histologic and inflammatory 
changes associated with TAC, but captopril was again unable to rescue the phenotype. To 
understand why, I investigated other receptors blocked by ACEis: the angiotensin II type 2 
receptor (AT2R) and the Mas receptor, a receptor for the Ang1-7 peptide. I found that 
cotreatment with captopril and an agonist for the AT2R had similar physiologic effects as 
the AT1R blocker despite being unable to prevent the fibrotic and inflammatory 
remodeling. In contrast, cotreatment with captopril and an agonist for the Mas receptor 
blocked remodeling but did not rescue aneurysm formation. My results, coupled with 
clinical data, indicate that fibrosis may be beneficial in the aorta, and show we must 
expand our understanding of the angiotensin system in aortic disease. 
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Chapter 1 – Introduction 
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1.1 – Structure of the aorta 
The aorta is the largest vessel in the body, originating from the heart and serving as 
a conduit for blood flow to the rest of the body. Anatomically, it is divided into multiple 
sections, starting with the aortic valve (aortic annulus), then the aortic root with the 
sinuses of Valsalva, where the left and right coronary arteries branch off to provide blood 
to the heart (Figure 1.1). The junction between the root and ascending aorta is the 
sinotubular junction, and the tubular ascending aorta extends to the arch.  The innominate 
artery branches off the aortic arch and divides into the right subclavian artery and right 
common carotid artery. The segment through the aortic arch is also known as the 
transverse aorta, and the left common carotid artery branches off this segment of the 
aorta followed by the left subclavian artery. The descending thoracic aorta runs along the 
spine and is where the intercostal arteries originate. Once the aorta passes the diaphragm, 
it becomes the suprarenal abdominal aorta and, eventually, the infrarenal abdominal aorta 
below the branches of the left and right renal arteries. The aorta ends where it branches 
into the left and right iliac artery (1, 2).  The sections of the aorta arise from distinct 
embryologic origins, experience distinct biomechanical pressures, and as a result may 
respond differently to different stimuli (3, 4). In the ascending aorta, all the smooth muscle 
cells are of neural crest cell origin. In the aortic root, these cells are derived from the 
second heart field (3). In the research presented here, the focus is on the aortic root and 
ascending aorta. 
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Figure 1.1 – Anatomical figure of the aorta from the heart to the pelvis starting from the 
aortic valve annulus where the blood leaves the heart through the aortic valve. The focus 
of the research presented here is primarily at the aortic root, which includes the sinuses of 
Valsalva, and the ascending aorta. The pathology associated with each segment of the 
aorta can be different, in part due to the different developmental origin of the SMCs and 
the hemodynamic flow patterns. Reprinted with permission from Journal of the American 
College of Cardiology (Weinsaft JW, Devereux RB, Preiss LR, Feher A, Roman MJ, Basson CT, 
Geevarghese A, Ravekes W, Dietz HC, Holmes K, Habashi J, Pyeritz RE, Bavaria J, Milewski K, 
LeMaire SA, Morris S, Milewicz DM, Prakash S, Maslen C, Song HK, Silberbach GM, Shohet 
RV, McDonnell N, Hendershot T, Eagle KA, Asch FM, Investigators GR. Aortic Dissection in 
Patients With Genetically Mediated Aneurysms: Incidence and Predictors in the GenTAC 
Registry, 2016) (1) 
 
The aortic is an elastic artery and the aortic wall is composed of three layers: the 
tunica intima, tunica media, and tunica adventitia. As shown in Figure 1.2, the tunica intima 
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is composed of a single layer of endothelial cells that, under normal physiologic conditions, 
rests on the internal elastic lamina and signals changes in sheer stress to the cells 
underneath (5-7). Between the internal elastic lamina and the external elastic lamina lies 
the tunica media which is the layer containing the smooth muscle cells. In the aorta, the 
tunica media is composed of layers of elastin with smooth muscle cells (SMCs) in between, 
with all layers laid down during development. In humans, there are approximately 50 
layers. The number of layers varies in different species, and this number has been shown to 
depend on multiple factors like weight, diameter, and pressure (6). The number of elastin 
lamellae/SMCs can also vary in genetically-engineered mouse models (6, 8-11).  The layers 
of elastin provide the aorta with the elasticity required to store the energy of the heart 
beat when the aortic valves close and maintain the blood pressure for continuous blood 
flow. This is referred to as the Wendkessel effect. Approximately 50% of the stroke volume 
has been reported to be stored in the aorta and proximal blood vessels to perfuse the 
peripheral tissues, but some reports indicate that pharmaceuticals can manipulate it (12).  
In the aorta, the SMCs are arranged in concentric rings between the elastin layers. 
Microfibrils, in which the major protein is fibrillin, are at the tips of elastin extensions 
extend from the elastin lamellae and bind to dense plaques or focal adhesions on SMCs 
(13) (Figure 1.3). At the cell surface, dense plaques or focal adhesions connect the 
microfibrils to the cellular network of contractile filaments, which are made up of the 
smooth muscle specific isoforms of α-actin (SM α-actin) and myosin heavy chain (SM-
MHC). Together, this apparatus of connecting cells and matrix has been termed the 
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“elastin-contractile unit,” (9, 14) and as discussed below, perturbations in this unit may be 
an important cause of thoracic aortic disease. 
The outer layer of the aorta, the tunica adventitia, is composed of fibroblasts and 
can contain inflammatory cells with some diseases. In addition, this layer also contains 
stem cells capable of differentiating into multiple cell types in the vessel wall but their 
significance, function, and origin are still under debate (15-19).   From a clinical and 
physiological perspective, the extracellular matrix in the adventitia is composed mostly of 
collagen, which provides the vessel with the structural integrity to support the wall of the 
vessel against high intraluminal pressures.  In humans, this layer is also where the vasa 
vasorum (blood vessels of the blood vessel) reside, providing oxygen and nourishment to 
the vessel wall (13, 20). 
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Figure 1.2 – Histology of the aortic wall. A) A hematoxylin and eosin (H&E) stain of a wild 
type (WT) mouse aorta. Most of the vessel wall observed is the media with minimal 
adventitia and a single layer of endothelial cells. Normally, in mice there is not a sizeable 
amount of adventitial layer. B) The adventitial layer is much larger with some forms of 
aortic pathology. H&E stain of biomechanically stressed ascending mouse aorta to show 
the expansion of the adventitia. C) A Movat stain of the stressed aorta demonstrating the 
lumen, media (dark), and adventitial layer, which is composed of cells (red), collagen 
(yellow, poorly visualized due to the proteoglycan deposition), and proteoglycans (blue). D) 
At higher magnification, the elastin fibers can be seen in black in the medial layer. While 
not present in mice, the adventitia would be the location of the small arteries of the vasa 
vasorum. 
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Figure 1.3 – A drawing of the transverse and longitudinal cross section of the vessel wall 
demonstrating the contractile unit. Elastin layers (dense black) are arranged between the 
smooth muscle cells, and the contractile fibrils are connected to them in the cell. Reprinted 
with permission from Lab Invest (Davis EC. Smooth muscle cell to elastic lamina 
connections in developing mouse aorta. Role in aortic medial organization, 1993) (14) 
 
1.2 – Thoracic aortic disease and pathology 
Thoracic aortic aneurysms and dissections are a major clinical concern, and 
constitute some of the most devastating pathologies plaguing patients. The natural history 
of thoracic aortic aneurysms is that they enlarge over time, and with this expansion, are 
predisposed to acute aortic dissections.  With multiple possible presentations, the 
diagnosis of thoracic aortic dissections is often missed by physicians. Acute pain in the 
upper thorax radiating to the back or to other parts of the chest can often be mistaken for 
a minor ailment, when, in fact, it is an aortic dissection and a clinical emergency.  
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Figure 1.4 – Aortic aneurysm formation can lead to aortic rupture or dissection. Far left is 
an illustration of a root aneurysm and ascending aortic aneurysm. Stanford Type A 
dissections are depicted in the middle. They encompass the ascending aorta and are 
considered a clinical emergency. A Stanford Type B dissection is anything distal of the left 
subclavian artery (depicted far right). Uncomplicated dissections are medically managed 
and electively repaired. 
 
Thoracic aortic aneurysms are closely monitored in patients because they are often 
the precursor to an aortic dissection or aortic rupture. A rupture of the vessel wall results 
in blood leaving the vascular system causing a patient to bleed out or, depending on the 
location, compromise other organs near the structure. A dissection is more complex. The 
structure of the vessel (aorta) becomes compromised as the aorta enlarges, and a tear in 
the intima allows blood to enter the vessel wall. The blood separates the vessel wall 
creating a true and false lumen with the false lumen often being located in the medial layer 
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of the wall. Blood pressure builds in the false lumen, and the increase in pressure can cause 
the dissection to progress proximally or distally down the vessel wall. The pressure in the 
false lumen can often collapse or restrict the blood flow in the true lumen causing distal 
malperfusion with clinical symptoms. Furthermore, a dissection can lead to rupture and a 
patient exsanguinates out if the vessel ruptured is in a large enough compartment of the 
body (21, 22). 
Aortic aneurysms and dissections are commonly classified by the Stanford 
Classification System, which identifies the need for immediate surgical intervention. Other 
classification systems of dissection, such as the DeBakey Classification System are also used 
(23). Any dissection between the aortic valve and the left subclavian artery is considered a 
Stanford Type A dissection. This is considered a surgical emergency as the dissection can 
cause a stroke distally or a hemo-pericardium proximally.  Normally, these dissections 
require emergent replacement of the vessel or more depending on the patient.  Stanford 
Type B dissections are distal to the left subclavian artery. Often, these cases are medically 
managed but closely monitored. They are only surgically addressed if there are 
complications such as mesenteric ischemia, paralysis, or untreatable pain (23). 
A vascular aneurysm is defined by a ballooning of a vessel to 1.5 times its normal 
size, and indicates a weakening of the vessel wall. Aneurysm formation is accompanied by 
pathologic changes that strain the wall, alter its structure, and in theory change the flow 
mechanics (24-27).  In the aortic root and ascending thoracic aorta, the pathology 
associated with aneurysms is usually characterized by a disordering and fragmentation of 
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the elastic fibers along with an increase in inflammation. Inflammatory markers produced 
by vascular SMCs and fibroblasts, such as IL6 and MCP1, signal inflammatory macrophages 
to invade the vessel wall. The macrophages then recruit fibroblasts to begin remodeling 
the medial layer and alter the extracellular matrix (28). While the origin of the fibroblast 
have been debated (17), they differentiate into myofibroblasts and induce the remodeling 
process, including the production of matrix metalloproteases (MMPs), to alter the vessel 
wall by cleaving multiple target proteins in the extracellular matrix (29). The remodeling 
includes changes in the extracellular matrix with alterations or fragmentation of elastin 
fibers, the production of proteoglycans, and the production of adventitial collagen (28, 30). 
These changes lead to a loss of the highly structured matrix organization described above. 
The resulting disruption of the “elastin-contractile unit” structure can cause aberrant 
changes in smooth muscle cells such as apoptosis (31) or hyper-proliferation (5, 9, 11).    
By far the most important risk factor for thoracic aortic aneurysms and dissection 
(TAAD) is hypertension.  Other factors that increase blood pressure and biomechanical 
forces on the ascending aorta are body building, weight lifting, and illegal drug use 
(cocaine, methamphetamines). Approximately 75% of patients with TAAD have elevated 
blood pressure, making it the most significant co-factor in the disease (32).  Other factors 
that increase the risk for thoracic aortic disease include age and the presence of a bicuspid 
aortic valve (8). The disease is significantly more common in males than females. In the 
studies reported here, Chapter 4 describes the role of increased biomechanical forces on 
the ascending aorta in aortic aneurysm formation.    
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There are also multiple genetic changes that predispose to thoracic aortic disease.  
Clinical studies have shown that up to 25% of TAAD patients have a first degree relative 
with the disease (33-35). These cases with an inherited predisposition can have syndromic 
forms of the disease, including Marfan syndrome or Loeys-Dietz syndrome, or can lack 
syndromic features. Genetic variants leading to TAAD are typically inherited in an 
autosomal dominant pattern with reduced penetrance and variable expression (36). 
Mutations contributing to the disease have been found in cell adhesion proteins (FBN1, 
COL3A1) (37, 38), transforming growth factor-beta (TGF-β) pathway genes (TGFBR1, 
TGFBR2, SMAD3, TGFB2) (5, 39, 40), genes encoding proteins involved in SMC contraction 
(ACTA2, MYH11, MYLK) (41-44), and genes associated with survival and metabolism(FOXE3, 
MAT2A)(8, 45). Marfan syndrome is caused by mutations in FBN1, which encodes fibrillin-1, 
the major component in the microfibrils that link elastin with SMCs in the aorta. Many of 
these genes have been extensive studied for their relationship to the canonical TGF-β 
pathway. The data presented in this dissertation will focus on mutations in the gene 
encoding SM α-actin (ACTA2), which were identified by our lab in 2007 (41).  
 
 
 
 
 
12 
 
 
 
1.3 Angiotensin system 
 
Figure 1.5 –Angiotensinogen is converted to angiotensin I, which is then converted to 
angiotensin II via angiotensin converting enzyme (ACE). There are multiple therapeutics 
developed that alter this pathway, such as ACE inhibitors and AT1R blockers. 
 
The renin-angiotensin system (RAS) is system that regulates blood pressure. In 
response to changes in blood pressure, angiotensinogen, an α2-globulin, is produced by the 
liver and converted by renin to angiotensin I (AngI).  An angiotensin converting enzyme 
(ACE) on the surface of pulmonary and renal endothelium then converts angiotensin I to 
angiotensin II (AngII) which binds to AngII receptors to alter multiple cells in the body and 
adjust blood pressure.  Through the angiotensin II type 1 receptor (AT1R) it leads to the 
release of a mineralcorticoid, aldosterone, from the adrenal glands which increase sodium 
reabsorbortion kidneys to help control blood pressure (46, 47). There are two 
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pharmaceutical strategies to alter this pathway that are currently used extensively in 
patients, one via inhibition of ACE inhibitor (ACEi) the second blocking the AT1R (24).  
However, the angiotensin system is much more complex. There is more than one receptor 
for angiotensin II (48-51). The AT2R has different effects in cells than the AT1R. 
Additionally, there is more than one ACE. The second ACE, ACE2, can convert angiotensin I 
and angiotensin II to smaller peptides Ang1-9 and Ang1-7, respectively, which lead down a 
different pathway triggering the Mas receptor.  Additionally, Ang1-9 is converted by ACE to 
Ang1-7, which is the ligand for the Mas receptor. These pathways are further discussed 
below and shown in Figure 1.6. 
 The AT2R has been known to counter the effects of the AT1R downstream in 
multiple systems. In the vascular SMCs, the AT1R increases proliferation, fibrosis, MMP2, 
and MMP9 expression (52), while the AT2R decreases proliferation, fibrosis, and MMP9 
expression (48).  However, in some models the AT2R has been thought to affect smooth 
muscle cell apoptosis (53, 54). Evidence indicates that Ang1-9 is converted by ACE to Ang1-
7.  With Ang1-7 binding to the Mas receptor on cardiomyocytes, it increases heart function 
improving cardiac output, cardiac index, and fractional shortening. It also reduces 
cardiomyocyte hypertrophy, fibrosis, and inflammation, but the Ang1-7 peptide and AngII 
have been viewed as having different effects on different physiologic systems, commonly 
focused on inflammation and fibrosis (55, 56). 
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Figure 1.6 – The revised view of the renin-angiotensin system. AngII can activate both the 
AT1R and AT2R receptors. AngI and AngII can both be metabolized by a second ACE 
enzyme into angiotensin peptides Ang1-9 and Ang 1-7, respectively.  
 
1.4 Angiotensin in animal models 
The role of the angiotensin system in aortic disease has been studied extensively in 
mouse models. The infusion of AngII into a mouse at a high enough dose can cause aortic 
disease. Most of the studies on angiotensin infusions focus on abdominal aortic aneurysms, 
since this and increased blood pressure are the most common presentations with this 
model, but expansion and dilation of the ascending aorta coupled with structural changes 
are also seen (57). AngII infusion causes medial expansion via hypertrophy or hyperplasia in 
both the abdominal and the thoracic aorta. Additionally, it has been shown to increase 
inflammation with the secretion of inflammatory cytokines by fibroblast and cells in the 
adventitia to recruit monocytes which further stimulate fibroblasts to remodel and 
increase cytokine production. Of note, however, blood pressure does not play the only role 
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as an increase in blood pressure with norepinephrine does not have the same effects (28, 
30, 58).  
There have been multiple studies using manipulation of the angiotensin system in 
genetic models of aneurysm formation to study the role of this pathway in driving the 
disease. There are a few different mouse models of Marfan syndrome which have variable 
effects on pathology and survival. These models include models that are deficient in 
fibrullin-1 (Fbn1-/-) (59) or express only a small percentage of normal fibrillin Fbn1mgR/mgR(8, 
60). One of the most established models is the Fbn1C1039G/+ mouse model (61, 62), which is 
viable and exhibits slow aortic growth. This mouse is heterozygous for a missense mutation 
that results in production of mutant fibrillin-1. In these mice, it was shown that the 
traditional beta-blocker (propranolol) and TGFβ neutralizing antibodies were able to 
reverse some of the aortic pathology. The idea was that propranolol would decrease blood 
pressure and stress on the aortic wall and the TGFβ neutralizing antibodies would block 
pathologic TGFβ signaling. However, an Angiotensin II type I receptor blocker (ARB), 
losartan, had a more drastic effect altering the structure of the aortic wall with decreased 
elastin fiber disruption, decreased wall thickening, and decreased distance between the 
elastic fibers (61). This echoes multiple studies showing the beneficial effects of blocking 
the AT1R or knocking it out in mice not just in the aorta, but also the heart (63, 64). 
One study also focused on the effects of the AT2R. Agtr2-/- mice were crossed with 
Fbn1C1039G/+ mice, which lead to an increase in pERK signaling, a downstream indicator of 
AT1R signaling (48). These results indicated that the AT2R may counter many of the 
16 
 
intracellular effects of the AT1R. Another mouse model of TAAD with a deletion in fibulin-4 
(Fbln4-/- mice) causes aneurysm formation with severe medial degeneration along with a 
loss of SMC differentiation and hyper proliferation. In these Fbln4-/- mice, the angiotensin 
converting enzyme inhibitor captopril was shown to be just as effective as losartan: 
initiating treatment with either drug in the first month of life attenuated the growth of the 
aorta and reduced pathologic changes in this model (65). 
Our lab developed a more acute biomechanical model, in which I focused on hyper-
acute aortic remodeling model using transverse aortic constriction (TAC) (52).  The model 
was originally designed to mimic congestive heart failure and has been studied extensively 
in congestive heart failure and left ventricular hypertrophy (66).  Over two weeks I saw an 
increase in proximal aortic size of 23%. There was an increase in the thickness of the media 
and adventitia. Medial cell density did not change, but cell density did increase in the 
adventitia. Inflammatory markers rose significantly as indicated by expression of IL6 and 
MCP-1. Additionally, I observed an increase in matrix remodeling genes MMP2 and MMP9. 
I also observed evidence of increased TGFβ signaling. As in other studies, losartan 
attenuated many of the pathophysiologic changes associated with this model. Specifically, 
losartan attenuated aortic growth, reduced medial thickening, and blocked the 
inflammatory response including the infiltration of macrophages. However, losartan was 
not able to completely reverse the changes in the adventitial layer, including thickening, 
collagen production, and signaling changes (52). Our data, combined with the prior studies 
by other labs (61, 65), indicate that AT1R may be a therapeutic target in ascending aortic 
disease. 
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1.5 Hypothesis tested 
I hypothesize that angiotensin II signaling through the AT1R contributes to 
thoracic aortic aneurysm formation in multiple model systems of disease, but that 
blocking related receptors in addition to the AT1R, such as the AT2R and Mas receptor, 
may have no effects or negative consequences.  
Herein, I demonstrate that losartan prevents aortic aneurysms in a mouse model of 
ACTA2 mutations, Acta2-/- mice, but captopril increases the growth of the aorta.  Instead of 
increased production of AngII in the aorta, I determined that the loss of α-actin filaments in 
aortic SMCs increases NF-κB signaling, thus driving increased expression of AT1R receptor, 
sensitizing the cells to exogenous AngII.  Furthermore, I show that in an acute 
biomechanical stress model, blocking AngII production using an ACE inhibitor (captopril) is 
not sufficient to reverse the aortic enlargement associated with the increased pressure. 
The addition of an AT2R agonist coupled with captopril prevented aortic growth in a 
manner similar to losartan.  Lastly, unrecognized congenital abnormalities in the aorta of 
the Agtr1-/- mice prevented the use of this model to confirm that losartan prevention of 
aortic enlargement with increased biomechanical forces was specifically due to blocking 
the AT1R receptor. This is an unexpected, totally novel observation. 
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Chapter 2 – Methods 
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2.1 Introduction 
Similar methods are used in all projects and will be described in this section. When I 
chose to make small adjustments from these approaches in different projects, I will 
mention those accordingly. 
 
2.2 Mouse models 
Mice were housed either at the animal care facility (CLAMC) at The University of 
Texas Health Science Center McGovern Medical School Building or in the Mouse 
Cardiovascular Phenotyping Core at Baylor College of Medicine. Wild type (WT) mice for 
transverse aortic constriction (TAC) were all acquired from Jackson Labs (Bar Harbor, ME, 
C57BL/6J Stock No:000664) at 10-12 weeks of age. Upon arriving, mice were quarantined, 
and the TAC surgery was performed at 12-14 weeks of age. Mice were sacrificed two weeks 
post-operatively as described below. Our lab had previously obtained frozen embryos of 
the Acta2-/- mouse from Dr. Warren Zimmer at Texas A&M, originally designed by 
Schildmeyer et al and bred into a C57BL6 background (67). Acta2-/- mice were then bred in 
house for our studies. In our Agtr1a-/- studies, mice were acquired from Jackson Labs (B6. 
129P2-Agtr1aTm1Unc/J, Stock No: 002682). Studies with TAC and Acta2-/- treated with 
captopril were all male while the other studies consisted of both male and female mice. 
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2.3 Transverse aortic constriction (TAC) 
All mouse experimental procedures were approved by the Animal Welfare 
Committee at The University of Texas Health Science Center McGovern Medical School and 
the Animal Welfare Committee at Baylor College of Medicine Mouse Phenotyping Core. 
C57BL/6J mice were purchased from Jackson Laboratories (Bar Harbor, ME) at 10-11 weeks 
of age. As previously described in Kuang et al (52), mice were administered buprenorphine 
preoperatively (0.1 - 2.5 mg/kg subcutaneous injection). Mice were then given 2 – 2.5% 
isoflurane with 0.5 to 1.0 L/min of 100 % oxygen via a nose cone. Neck and chest hair was 
removed and the surgical site was prepared with chlorohexidine and 70% ethanol. Surgical 
instruments were sterilized chemically or by steam autoclave and the surgical area 
prepared accordingly. Sterile technique was used throughout.  For surgery, the mouse was 
placed in a supine position. After administering bupivacaine, a midline incision was made 
and superficial tissues were divided to expose the trachea to intubate the trachea using an 
18 – 21 gauge catheter. The catheter was then connected to a rodent ventilator (MiniVent, 
Type 845) administering 100% oxygen and 2 – 2.5% isoflurane. Mice were kept at a 
respiratory rate of 100-125 breaths per minute with a tidal volume of approximately 0.15-
0.25 mL. A partial sternotomy was performed to the second rib and the thymus divided to 
expose the transverse aorta.  A blunt 27 gauge needle was placed on the transverse aorta 
between the right innominate and left carotid artery.  Constriction was then made by tying 
a 6-0 non-absorbable braided black silk suture around the transverse aortic arch and 
needle. The needle was removed yielding the constriction.  The chest was closed with two 
interrupted vicryl 5-0 sutures after the lungs were re-inflated by closing of the outflow on 
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the rodent respirator. The skin was closed using 5-0 non-absorbable suture which was 
removed 10 days post-operatively. Anesthesia was discontinued and the animal extubated 
once it resumed spontaneous breathing.  Mice were monitored closely post-operatively for 
signs of distress and discomfort. The sham group underwent an identical procedure but no 
suture was tied to the aorta. Adequacy of the constriction was confirmed by Doppler flow 
studies, echocardiography, and catheter measurements described below. 
 
Figure 2.1 –The mice are constricted at the site of the transverse aorta leading to an 
increase in ascending aorta and aortic root size at two weeks. With the proximal increase in 
pressure, flow in the right carotid would increase significantly compared to the left carotid 
and there would be a significant pressure drop across the site of the constriction. 
 
2.4 Echo & Doppler studies 
Echocardiographic, Doppler, and blood pressure studies were all done in 
accordance with protocols previously described (11, 52). Under anesthesia, measurements 
were performed with a Vevo700, Vevo2100, Vevo3100, or an Indus Instruments Doppler 
system. Briefly, for all echo studies the mice were weighed and placed under anesthesia 
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with isoflurane administered and maintained via nose cone with a dose of 1 – 2% 
isoflurane at a rate of 0.5 to 1.0 L/min of 100 % oxygen. Mice were maintained under 
anesthesia for the duration of the experiment with a goal heart rate of 300 to 400 bpm. 
Heart rate and temperature were continuously monitored, and the temperature 
maintained within normal limits using the Indus Instruments pad and system. I observed 
some variability in response to anesthesia even within groups, with some mice appearing 
more sensitive to the anesthesia. Therefore, anesthesia was adjusted accordingly. All 
images were obtained in a parasternal long-axis view with 40 MHz ultrasonic probes. 
With all experiments performed with the Vevo700 and Vevo2100 systems 
(VisualSonics, Toronto, Ontario, Canada), the mice were placed in a supine position on the 
monitoring pad angled slightly to the mouse’s left side. Images of the ascending aorta and 
aortic root were then obtained and multiple videos recorded for each mouse. Under similar 
monitoring and anesthesia, Doppler measurements were made with the Indus Instruments 
Doppler probe one week post-operatively and recorded with their Doppler Signaling 
Processing Workstation with the mouse supine. 
The same procedures were performed using the Vevo3100 (VisualSonics, Toronto, 
Ontario, Canada) for ascending and aortic root measurements. However, with the 3100 
system, with the mice still sedated, I also assessed cardiac function and flow across the 
constriction at the transverse aorta, left common carotid artery, and right common carotid 
artery. Flow across the transverse aorta was obtained with the mouse still in the supine 
position. Cardiac function was assessed by obtaining both longitudinal and transverse 
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views across the left ventricle with the animal tilted slightly to its right in the supine 
position. Images over the left common carotid artery and right common carotid were 
obtained with the mouse in the Trendelenburg position. 
All mice were removed from isoflurane and allowed to recover. Flow studies of the 
common carotid arteries using the Vevo3100 correlated with the Indus Instruments 
Doppler studies. These studies were done using similar techniques, but the mice were not 
required to have their hair removed. 
Images of the ascending aorta and aortic root were then obtained, recorded, and 
later analyzed using VevoLAB 1.7.1 (VisualSonics, Toronto, Ontario, Canada) or Sante 
DICOM Editor 3.1 (Santesoft) (Figure 2.2). Carotid Doppler measurements were also 
analyzed with the VevoLAB 1.7.1 when obtained with either the Vevo 3100 or the Doppler 
Signal Processing Workstation, Ver 1.624 (Indus Instruments, Houston, Texas). 
 
Figure 2.2 – Echo image of the aorta in the longitudinal view. Measurements were taken at 
the ascending aorta and the aortic root. Images taken using the Vevo 700 and analyzed in 
the SanteDICOM Software. The red lines designate the measurements for the ascending 
aorta (left) and aortic root (right). The heart would be to the right of the image. 
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2.5 Non-invasive blood pressure monitoring and blood pressure measurements 
Non-invasive blood pressure monitoring was performed via a tail cuff system and 
were not utilized in TAC experiments. Briefly, awake mice were immobilized, and a blood 
pressure cuff placed over the tail. Mice were then placed on a heating pad and the blood 
pressure was recorded for five minutes with a CODA Noninvasive Blood Pressure system 
(Kent Scientific Corporation, Torrington, CT). This procedure was repeated multiple days in 
a row in order to acclimate the mouse to the testing environment and technique. Only the 
measurements on day five were utilized for analysis. 
For TAC studies I utilized an invasive, non-survival catheterization technique with a 
SPR-1000 1F Catheter (AD Instruments, Sydney, Australia), a Pressure Control Unit PCU-
2000 (Millar, Houston, TX), a PowerLab 4/35 DAQ device (AD Instruments), and LabChart 
software (AD Instruments). Prior to the procedure, all surgical instruments and supplies 
were sterilized by steam autoclave, and the surgical field prepared in a sterile fashion. The 
1F pressure catheter probes were presoaked in saline or distilled water for 30 second 
before catheterization. Mice were anesthetized with isoflurane via nose cone using the 
same method previously described for echocardiography (Section 2.4). Ketoprofen was 
given subcutaneously at a dose of 2.5 mg/kg. Hair on the chest and throat was removed, 
and the skin was prepared with povidone iodine and alcohol. A longitudinal incision was 
made approximately 2 mm to the right of the midline of the throat, from the lower jaw to 
the sternum. The skin and overlying tissue was gently divided and the right carotid artery 
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exposed. Ligatures were then placed on the right common carotid artery at the proximal 
and distal sites.  The knot on the distal site was made tight, while that on the proximal 
location site was made loose around the artery. Using a hemostat, the artery was clamped 
proximal to the more proximal ligation site. A 27 G needle was then used to create a small 
hole near the distal ligation site. The catheter probe was then inserted and advanced past 
the proximal knot, and the knot tightened down around the probe. For reference, the 
depth to insert the probe into a carotid for an 11-week-old mouse would be about 12 mm. 
Next, the hemostat was removed and the blood pressure recorded for a 5-10 minutes. 
Afterwards, the mouse was euthanized, while still sedated, for studies described below. 
2.6 Drug administration 
Captopril and Losartan are orally administered drugs used in both our TAC and 
Acta2-/- trials. Captopril (Cat# sc-200566A, Santa Cruz Biotechnology) was administered at 
75 mg/L and Losartan Potassium (Cat# sc-204796A, Santa Cruz Biotechnology) was 
administered at 600 mg/L in the drinking water, as previously (52). For the studies using 
AVE0991 (Sanofi, Paris, France), captopril was given in the drinking water and AVE0991 
given by intraperitoneal (IP) injection at a dose of 576 ug/kg/d. Similarly, Compound 21 
(C21, Vicore, Moelndal, Sweden) was administered by IP injection at a dose of 300 ug/kg/d 
with or without captopril in the drinking water. 
For the Acta2-/- studies, mice were treated long term with captopril via drinking 
water at a dose of 75 mg/L starting at four weeks of age.  The mice remained on this dose 
until they were sacrificed at 13 months of age, for a total of 12 months of treatment. 
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Similarly, mice treated with losartan, were given 600 mg/L in the drinking water starting at 
4 weeks of age (11). Losartan treatment was continued for 10 months until sacrifice at 11 
months of age.  Some mice were also treated long term with doxycycline for approximately 
12 months starting at 4 weeks of age. Doxycycline was administered in their drinking water 
with 1% sucrose. Controls for all of these experiments were untreated mutant and WT 
littermates given drinking water, except in the doxycycline trial in which the control mice 
were given 1% sucrose water. The doxycycline doses were based on previous studies (63, 
68). 
Additional cohorts of Acta2-/- mice were treated short-term with L-NG-nitroarginine 
methyl ester (L-NAME) in their drinking water (3 g/L) in conjunction with a high salt diet 
(8% NaCl diet, Harlan), to make the mutant mice normotensive. Mice were started on L-
NAME and high salt diet at 4 weeks for age and treated for 3 months prior to sacrifice at 4 
months of age. 
2.7 Histomorphometric study 
Following completion of the echo, Doppler, and catheterization studies, animals 
were sacrificed.  After anesthetization with 2.5% avertin, transcardiac perfusion was 
performed with 10 mL of PBS for 5 minutes followed by fixation with 10 mL of formalin for 
5 minutes. The heart, aortic root, ascending aorta, descending thoracic, and left and right 
carotid arteries were then carefully removed and placed in 10% formalin overnight. On the 
next day, the tissue was cleaned, processed and embedded in paraffin wax in a transverse 
orientation.  Tissues were cut into 4 µm sections using a microtome and mounted on slides 
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for staining. Hematoxylin and eosin (H&E) staining was performed via standard protocols. 
Pictures of the vessel cross-sections were taken at 40x, 50x, 200x, and 400x magnification. 
The luminal, medial, and adventitial areas were measured for each vessel in ImageJ. In 
addition, cell density was also assessed utilizing ImageJ. Movat staining was used to assess 
the structure, elastin breaks, and the amount of elastin and proteoglycan in the vessel wall. 
Additional staining of Mac-2 cells (anti-Mac-2 monoclonal antibody for macrophages), 
Sirius Red, and α-actin (anti-SMC α-actin specific antibody) were also obtained to look at 
inflammation, collagen production, and smooth muscle cells/fibroblast. TUNEL and PH3 
staining was also performed to analyze apoptosis and proliferation, respectively. Five or 
more mice were analyzed for each group and averaged, but the number of mice depended 
on the specific study. Some of the preliminary studies have smaller “n” sizes. Table 2.1 
shows the stains and antibodies utilized for these studies. 
 
Table 2.1 – Antibodies and stains utilized for IHC studies including their company and 
catalog number. 
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2.8 ImageJ analysis 
Images were recorded with a DP71 light microscope (Olympus, courtesy of 
Blackburn Lab) at 40x and 400x magnification, and all analysis was performed using ImageJ 
1.47v (NIH).  I utilized 40x magnification as a baseline and method of orientation for 
analysis. Cross-sectioned H&E’s at 40x were used to measure luminal area, vascular wall 
area, medial area, and adventitial area. Luminal area was defined as the area contained 
within the endothelium. However, in reality it is best measured to the internal elastic 
lamina, and echo measurements are considered a more physiologic standard. Vascular area 
was defined as everything from the internal elastic lamina to the tunica externa, the outer 
most defined layer of the vessel wall. Medial area was defined as the area between the 
internal elastic lamina and external elastic lamina. The adventitial area was defined as the 
area between the external elastic lamina and the tunica externa. Note this area was often 
omitted in the sham treated mice because it is very small and more difficult to quantify. In 
all mice, the endothelium is omitted since it is a single layer of cells and also difficulty to 
quantify. 
The 40x images were used to select sections at equivalent locations that were 
appropriately distributed throughout the aortic wall for analysis. The majority of the 
analysis was done at 400x. On H&E stained sections, cell nuclei were counted using a cell 
counter and individually the cellular density of the media and adventitia was determined in 
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each image. Over 6 images were analyzed for each section and averaged to calculate, 
which I once normalized to the area of each image. Measurements were verified by looking 
at multiple cuts of the same aorta. 
Images for Movat analysis were taken in a similar fashion at 400x magnification and 
analyzed in ImageJ. All components stained by Movat (elastin, collagen, proteoglycan, 
fibrin and smooth muscle cells) were assessed and presented as percentages registered 
pixels of the segment of interest for quantification. I focused primarily on elastin (black), 
proteoglycans (blue), and the cells which stained (red). A band pass filter was used for 
analysis, which allowed us to identify color thresholds for hue, saturation, and brightness 
for each measured component (i.e. elastin, proteoglycan, and smooth muscle cells). The 
resulting images were then used for quantification by the number of pixels.    
 Mac-2 staining was quantified by manually counting the total number of Mac-2 
positive cells in each section. The sirius red, TUNEL, and PH3 stains and images were not 
quantified for the purpose of these studies. 
 
2.9 Measurement of ROS in aortas by dihydroethidium (DHE) 
Descending aortas were harvested, rinsed immediately in cold PBS, placed in Tissue-
Tek OCT compound (Miles Laboratories), and snap frozen in liquid nitrogen. Blocks were 
cut to 30 μm-thick cryosections on a cryostat. Frozen sections were fixed in 4% PFA at 
room temperature for 15 minutes and rinsed 3x with PBS. DHE (Invitrogen, Cat#C10422) 
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stock at 2.5 mM was diluted for a final concentration of 10 μM in PBS and applied to each 
tissue section. Slides were incubated in a light-protected humidified incubator at 37°C for 
30 minutes. DHE was counterstained with DAPI. Sections were imaged within 8 hours of 
staining with a fluorescent ZEISS AXIOSKOP 40 microscope. Identical acquisition settings 
were used for tissue from wild-type or mutant animals. Fluorescence images were 
quantified with ImageJ. Integrated fluorescence intensity (IFI) was calculated by integrating 
the area and strength of red staining within the aortic wall in each image. Error bars 
represent standard error. 
 
2.10 RNA extraction and qPCR  
Following the echo, Doppler, and catheterization studies, RNA was extracted from 
the ascending and descending aorta of a subset of the mice. For RNA extraction, the mice 
were perfused with saline and the tissue harvested, cleaned, and then flash frozen. Trizol 
(Invitrogen) was used for the extraction of RNA. RNA was then reverse transcribed using 
the cDNA Archive Kits (Life Technologies) or iScript cDNA synthesis kit (Bio-Rad) following 
the manufacturer protocols. For real-time PCR analysis of mRNA expression, I utilized both 
TaqMan (Applied Biosystems, Foster City CA) and SyberGreen primers.  SybrGreen probes 
were designed as described in the Table 2.2 with references. When mentioned, I 
acknowledge the catalog number for the Taqman probes that were used. Experiments 
were performed in triplicate, and Gapdh was used as an endogenous control for each run. 
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Table 2.2 – Primers designed from SybrGreen utilized in our studies. 
“2.11 2D-gel electrophoresis  
Cultured SMCs or freshly isolated ascending aortic tissue were 
homogenized in urea sample buffer, containing 8M urea, 20mM Tris, 
23mM glycine, 0.2mM EDTA, 5% saturated sucrose, and 10mM DTT. 
Three micrograms of cell lysates mixed with or without 200ng of purified 
SM α-actin or SM γ-actin (provided by Dr. Kathleen Trybus from the 
University of Vermont) were added into 450µL of Rehydration/Sample 
buffer (Bio-Rad). Samples were loaded onto 24 cm, pH 4–7, immobilized 
pH gradient strips (Bio-Rad) overnight and focused in a PROTEAN® i12™ 
IEF System (Bio-Rad) for 60kVh. Then, the strips were equilibrated in 
Equilibration Buffer I and II (Bio-Rad), the center third parts were cut out 
and saved, and the strips were gently inserted into a 8-12% SDS-PAGE 
mini-gel (Bio-Rad). Then, the gel was run, transferred to nitrocellulose 
membrane, blotted with anti-pan actin antibody (MA5-11869, Sigma), 
and visualized as described in routine immunoblotting. The calculated 
isoelectric points for α-, β-, and γ-actin are 5.24, 5.29, and 5.31, 
respectively. 
 
2.12 NADPH oxidase activity assay. 
Aortic tissues harvested from 2 months old mice (n=4 per group) 
were ground in chilled grinding vials and were homogenized in lysis 
buffer (20 mmol/l KH2PO4, 1 mmol/l EGTA, and protease inhibitors 
cocktail; pH 7.4) and sonicated for 5s (3x with 10s interval). The 
homogenates were then centrifuged at 750 g for 5 min. The pellet was 
discarded and the supernatant was collected and subjected to a 
lucigenin-enhanced luminescence assay as described before to determine 
NADPH oxidase activity in the aortic tissue homogenate (69). Protein 
content was measured in an aliquot of homogenate by Bradford assay. 
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NADPH oxidase activity was measured by chemiluminescence in a well 
containing assay phosphate buffer (50 mM KH2PO4, 1 mM EGTA, and 150 
mM sucrose; pH 7.4), 5 μM lucigenin (Sigma), and the sample (50 μl). 
Reactions (final volume, 250 μl) were initiated by addition of 100 μM 
NADPH (Sigma). Luminescence was measured every second for 5 min in a 
luminometer (BioTek Synergy™ HT; BioTek Instruments, Inc., Winooski, 
VT). A background value was subtracted from each reading. Activity was 
calculated from the ratio of mean light units to total protein level and 
expressed as arbitrary units (relative light unit).  
 
2.13 Calcium imaging 
  Cells were seeded on 25mm coverslips and pretreated with the 
indicated drugs for the indicated times. Cells were loaded with Fura-2AM 
for 10-15 minutes and then placed in the imaging chamber with 0.5mL of 
culture medium. Coverslips were mounted for viewing on a Nikon TE200 
microscope, and imaging was performed with Incytim2 software 
(Intracellular Imaging, Inc.). Measurements were taken using excitation 
wavelengths of 343/380 nm and emission wavelength of 520 nm. Basal 
Ca++ was assessed for 20 seconds, then 0.5mL of medium containing the 
indicated amounts of AngII was added to the chamber. Imaging 
continued until Ca++ levels returned to baseline. Data is represented as 
Fmax/F0 where Fmax represents the highest 340/380 ratio and F0 
represents the baseline 340/380 ratio for each cell.” 
 
Quoted text reprinted from Supplemental Information with minimal 
modification with permission from Wolters Kluwer Health (Chen J, Peters AM, 
Papke CL, Villamizar C, Ringuette LJ, Cao JM, Wang S, Ma S, Gong L, Byanova K, 
Xiong J, Zhu MX, Madonna R, Kee P, Geng YJ, Brasier A, Davis EC, Prakash SK, 
Kwartler CS, Milewicz DM. Loss of Smooth Muscle alpha-actin Leads to NF-
kappaB-Dependent Increased Sensitivity to Angiontensin II in Smooth Muscle 
Cells and Aortic Enlargement Circ Res 2017). See reference (11)   
 
 
 
2.14 Statistical analysis 
All data are expressed as mean ± standard deviation. Multiple groups were analyzed 
assuming unpaired, non-parametric analysis (Kruskal-Wallis). Differences between specific 
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groups were analyzed assuming unpaired, non-parametric analyses (Mann-Whitney U). All 
groups included 4 or more male mice depending on the study. I was limited by survival 
rates in some of the long term treated Acta2-/- mice although, the analysis consists of 5 or 
more animals for most of the studies. Statistical analysis and graphs were all produced with 
GraphPad Prism 6 (Version 6.03) or with Microsoft Excel. Differences were considered 
significant when p<0.05. However p values approaching the 0.05 limit may be reported if I 
felt that it was due to that experiment being underpowered. The Bonferroni correction was 
not performed. When shown in the figures, a * indicates p≤0.05, ** indicates p≤0.01, *** 
indicates p≤0.001, and **** indicates p≤0.0001. 
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Chapter 3 –The Acta2-/- mouse model of thoracic aortic disease: source of increased AngII 
signaling and pharmacologic manipulation of AngII signaling 
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3.1 Introduction  
As mentioned earlier, in patients with thoracic aortic aneurysm or dissection 
(TAAD), it has been shown that up to 20% of them have a genetic predisposition for the 
disease (33, 34). Although many of those patients have syndromic features such as Marfan 
syndrome, the majority do not have features of a syndrome. These patients show no 
specific distinguishable features to identify them to be at risk for thoracic aortic disease 
other than a family history of the disease. In these cases, ACTA2 is the most frequently 
mutated gene, accounting for 12-20% of the familial mutations making it a specific clinical 
concern. ACTA2 encodes the SMC-specific isoform of α-actin (SM α-actin), which makes up 
to 40% of SMC cellular protein. SMCs major function is contracting in response to stimuli, 
such as cyclic strain or neurostimulation. This cyclic contraction is mediated by sliding thin 
filaments composed of α-actin filaments over the thick filaments, composed of SMC-
specific β-myosin heavy chain and other proteins. ACTA2 variants causing thoracic aortic 
disease are missense mutations inherited in an autosomal dominant pattern, which have 
been shown in vitro to cause a dominant negative effect on SMC α-actin filament formation 
(5, 41). It is notable that ACTA2 is a highly conserved and invariable gene with essentially 
no variation in the general population. Missense variants throughout the protein have 
been identified and strong associations exist between specific genotypes and phenotypes 
(5). Recurrent mutations disrupting specific amino acids, such p.R179, p.R258, and p.R149, 
have sufficient clinical data to identify distinctive clinical phenotypes associated with each 
variant and allow for personalized management of the vascular disease associated with 
these variants (70-73). 
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To model vascular disease in patients with ACTA2 mutations, we used a mouse 
model with knock out of SMC α-actin, Acta2-/- mice. Prior studies had shown that Acta2-/- 
mice have normal vascular development, but the mice are hypotensive and aortic 
segments contract less with agonist stimulation (67). Work in our lab initially focused on 
characterizing the SMC phenotype and determined that Acta2-/- SMCs were hyperplastic 
due to activation of cellular pathways, involving FAK, platelet-derived growth factor 
signaling, and reactive oxygen species (ROS) (9). 
 In the studies described below, we sought to characterize aortic pathology in 
Acta2-/- mice and determine whether treatment with modulators of the angiotensin system 
could alter the pathology. I show that Acta2-/- mice have aortic enlargement, but this 
enlargement does not progress to dissection.  Furthermore, the aortic enlargement is 
attenuated by losartan treatment but exacerbated by captopril treatment. These results 
once again emphasize the complex role of angiotensin signaling in aortic disease. Through 
my investigations of the cellular mechanisms of aneurysm formation, we identified that 
increased NF-κB signaling is responsible for increased expression of Agtr1. The 
overexpression of Agtr1 leads to increased sensitivity of the aortic SMCs to endogenous 
AngII levels and drives enlargement of the aorta. My results show a completely novel 
mechanism by which angiotensin signaling can be increased in cells without an increase in 
local or systemic levels of AngII.  
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3.2 Results 
3.2.1 Acta2-/- mice and losartan treatment over time 
There was no difference in the size of the aortic root or the ascending aorta 
between Acta2-/- and WT mice at 4 weeks of age (Figure 3.1 A). By 6 months of age, a 
significant increase in the size of the aortic root in Acta2-/- mice was evident when 
compared to WT mice, and the aortic diameter continued to increase at 7 months of age 
(Figure 3.1 B). Interestingly, we observed these changes despite the fact that the Acta2-/- 
mice were significantly hypotensive compared to the WT mice (11).  Importantly, there was 
no significant difference in mouse survival between the mutant and WT mice (Figure 3.1 C).  
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Figure 3.1 – A) At four months of age there was no significant difference between the size 
of the ascending aorta and the aortic root between the WT and Acta2-/- mice. B) Over time 
the aortic root became significantly larger in the Acta2-/- by 20 weeks of age. C) There was 
no difference significant in survival between these mice and their WT littermates. D & E) 
Ascending aorta and the aortic root measurements at seven months of age in the Acta2-/- 
with and without treated with losartan. Losartan was able to attenuate the growth of the 
aortic root.  Note that the ascending aorta is not significantly enlarged in the Acta2-/- mice. 
Modified and reprinted with permission from Circulation Research (Chen J, Peters AM, 
Papke CL, Villamizar C, Ringuette LJ, Cao JM, Wang S, Ma S, Gong L, Byanova K, Xiong J, Zhu 
MX, Madonna R, Kee P, Geng YJ, Brasier A, Davis EC, Prakash SK, Kwartler CS, Milewicz DM. 
Loss of Smooth Muscle alpha-actin Leads to NF-kappaB-Dependent Increased Sensitivity to 
Angiontensin II in Smooth Muscle Cells and Aortic Enlargement. Circ Res 2017). See 
reference (11)   
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I also observed an increase in the number of elastin lamellae in the Acta2-/- 
postnatal aortas when compared to WT aortas (p<0.05, Figure 3.2 A, B). Elastic lamellae 
are laid down during development (7, 74), and the increased layers in the aorta can be 
observed in the histologic sections at every time point regardless of the treatments or 
procedures the mice went through postnatally. A similar phenotype is seen in mice 
deficient in elastin, Eln-/- mice (10). At 4 weeks of age Acta2-/- aortas also have an increase 
in the density of cells staining positive for a calponin, a SMC marker (Figure 3.3 A, C).  
However, the cell density normalizes to the same density as WT by 8 weeks of age, and the 
density remains the same as WT at all other time points assessed (Figure 3.2). This data 
suggests that the cellular proliferation phenotype and pathways that were previously 
identified in Acta2-/- SMCs do alter the development of aortic disease in this mouse.  The 
pathophysiologic changes seen between the observed groups were consistent with what 
we had previously observed in this model. In early studies, we found that there was a 
significant increase in the medial area of the Acta2-/- mice while there was no significant 
difference in medial cell density at older age. This would possibly indicate some form of 
cellular hypertrophy (Figure 3.5). However, the significant difference in medial cell density 
at a younger mouse age without increase in medial area may indicate that the cellular 
hyperplasia already exist after development.  
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Figure 3.2 – A) Aortic medial area increases significantly over time in the Acta2-/- mice 
compared to WT mice. B) Medial cell density was significantly higher in Acta2-/- mice 
compared to WT shortly after birth, however, the cell density between the mutant and WT 
were similar by 3 weeks of age. Modified and reprinted with permission from Circulation 
Research (Chen J, Peters AM, Papke CL, Villamizar C, Ringuette LJ, Cao JM, Wang S, Ma S, 
Gong L, Byanova K, Xiong J, Zhu MX, Madonna R, Kee P, Geng YJ, Brasier A, Davis EC, 
Prakash SK, Kwartler CS, Milewicz DM. Loss of Smooth Muscle alpha-actin Leads to NF-
kappaB-Dependent Increased Sensitivity to Angiontensin II in Smooth Muscle Cells and 
Aortic Enlargement, Circ Res 2017). See reference (11)   
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Figure 3.3 – Histologic analysis of the ascending aortas in mice at four weeks of age. A,B) 
Representative H&E, Movat, and calponin stains of the WT and Acta2-/- mice. (A) Show the 
increase in elastic lamellae and cells staining positive for calponin (quantified in B). 
Modified and reprinted with permission from Circulation Research (Chen J, Peters AM, 
Papke CL, Villamizar C, Ringuette LJ, Cao JM, Wang S, Ma S, Gong L, Byanova K, Xiong J, Zhu 
MX, Madonna R, Kee P, Geng YJ, Brasier A, Davis EC, Prakash SK, Kwartler CS, Milewicz DM. 
Loss of Smooth Muscle alpha-actin Leads to NF-kappaB-Dependent Increased Sensitivity to 
Angiontensin II in Smooth Muscle Cells and Aortic Enlargement, 2017) (11).  
 
Given that losartan blocked aortic enlargement in other mouse models of thoracic 
aortic disease (61, 63), we assessed whether losartan treatment could rescue the aortic 
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dilation and pathology in Acta2-/- mice. The mice were treated with losartan starting at 4 
weeks of age, and treatment continued for six months. The growth of the aortic root was 
attenuated with losartan treatment in the Acta2-/- mice compared to WT mice, indicating 
that losartan can partially prevent the age-dependent aortic growth (Fig 3.1-D,E). Acta2-/- 
aortas have minimal medial degeneration and the only significant change in aortic 
pathology in the mutant aortas compared with WT aortas was an increase in proteoglycan 
deposition in the medial layer, and this deposition was prevented by losartan. There were 
no significant differences in elastin breaks between Acta2-/- and WT mice. However, 
collagen deposition in the adventitial layer was borderline increased (p=0.07) and 
attenuated by losartan (p=0.08) (Figure 3.4).  
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Figure 3.4 – A) The H&E, Movat, and Sirius Red stains of the WT, Acta2-/-, and Acta2-/- 
losartan treated mice. The Movat stain colors indicate elastin (black), proteoglycans (blue), 
and the cells which stained (red). B) Analysis showed that there was a significant increase 
in the amount of proteoglycan in the wall of the Acta2-/- mice while there was significantly 
less with losartan treatment. C & D) showed that there is no difference in elastin breaks 
between the groups. It appears that adventitial collagen is increased, but our study is 
underpowered. Modified and reprinted with permission from Circulation Research (Chen J, 
Peters AM, Papke CL, Villamizar C, Ringuette LJ, Cao JM, Wang S, Ma S, Gong L, Byanova K, 
Xiong J, Zhu MX, Madonna R, Kee P, Geng YJ, Brasier A, Davis EC, Prakash SK, Kwartler CS, 
Milewicz DM. Loss of Smooth Muscle alpha-actin Leads to NF-kappaB-Dependent Increased 
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Sensitivity to Angiontensin II in Smooth Muscle Cells and Aortic Enlargement, Circ Res 
2017). See reference (11)  . 
 
3.2.2 Long term captopril treatment incapable of reversing pathological changes 
associated with Acta2-/- mouse model 
Losartan was able to attenuate aortic enlargement in the Acta2-/- mice. We 
therefore we wanted to further define the role of the angiotensin system in aneurysm 
formation and explore whether other therapeutic targets within this system might be 
effective. ACE inhibitors (ACEi) are upstream in the AngII signaling pathway of AngII 
receptor blockers, like losartan (Figure 1.5), we tested the use of an ACEi, captopril, in 
blocking aortic enlargement in the Acta2-/- mice. Habashi et al. found that they were able 
to inhibit aneurysm formation and the angiotensin pathway (65). This captured our interest 
given the clinical use of ACEi’s despite the fact that others noted that ACEi (enalapril) were 
not as effective in treating aortic aneurysm in Fbn1C1039G/+ (48). ACE inhibitors have been 
studied extensively in other tissues (75, 76). For this study, male Acta2-/- mice were treated 
for 10 months with captopril, with treatment beginning at 1 month of age. By 11 months of 
age, there was no difference in the aortic diameters between the Acta2-/- mice and WT 
mice.  Surprisingly, there was a significant increase in both the ascending aorta and aortic 
root diameter in the Acta2-/- mice treated with captopril compared to WT and untreated 
Acta2-/- littermates (Figure 3.4 A & B). Because larger mice tend to have larger aortas, we 
also analyzed the data normalizing the aortic size to the weight for all mice. There was no 
significant difference in the weight of WT and Acta2-/- mice, but treatment with captopril 
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significantly decreased their weight (Figure 3.4 C).  As a result, when we normalized to 
weight, the difference between the ascending aorta and aortic root size between the mice 
becomes more significant even in the ascending aorta (Figure 3.4 D & E).  
 
Figure 3.5 – A, B) Ascending aortic (A) and aortic root (B) measurements at 11 months of 
age and 10 months of treatment show that captopril treatment exacerbates the phenotype 
of Acta2-/- mice. C) Acta2-/- mice treated with captopril weigh significantly less than wild-
type. D, E) Normalizing to weight increases the significant differences between the groups. 
* indicates p≤0.05 and ** indicates p≤0.01 in the analysis. (Andrew M. Peters, Zhen Zhou, 
Jiyuan Chen, Alexandra Janda, Corey L. Reynolds, Shao-Qing Kuang, Shanzhi Wang, 
Siddharth Prakash, GenTAC Consortium, Callie S. Kwartler, Dianna M. Milewicz 
Pharmacologic Manipulation of the Angiotensin System Affects Aortic Remodeling and 
Aneurysm Development: Cautions for Clinical Practice, Submitted 2017) See reference (77). 
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Despite exacerbating the dilation of the aorta, captopril treatment did reverse some 
of the pathologic changes associated with Acta2-/- aortas. Specifically, the increased medial 
and adventitial areas were decreased with captopril treatment. These results suggest that 
the thickening of the adventitia and the media is actually protective. Captopril treatment 
had no effect on proteoglycan deposition but did increase elastin content in the aortic wall. 
The cellular hypertrophy that causes the medial thickening over time does not happen in 
the captopril treated aortas, so while elastin content remains constant, the amount of cells 
in the wall is lower in the captopril treated mice (Figure 3.6). 
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Figure 3.6 – A) H&E and Movat stains of the WT, Acta2-/-, and Acta2-/- mice treated with 
captopril. B & C) Analysis indicates that the Acta2-/-mice have a significant increase in the 
medial area and the adventitial area. These increases are not seen in the Acta2-/-captopril 
treated mice. D) There was a significant increase in the amount of elastin in the medial wall 
of the captopril treated mice compared to both the WT and untreated Acta2-/-mice. 
(Andrew M. Peters, Zhen Zhou, Jiyuan Chen, Alexandra Janda, Corey L. Reynolds, Shao-Qing 
Kuang, Shanzhi Wang, Siddharth Prakash, GenTAC Consortium, Callie S. Kwartler, Dianna 
M. Milewicz Pharmacologic Manipulation of the Angiotensin System Affects Aortic 
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Remodeling and Aneurysm Development: Cautions for Clinical Practice, Submitted 2017) 
See reference (77). 
 
“To investigate the increased signaling through the Agtr1a in 
Acta2−/− mice, SMCs were explanted from the ascending aorta. Our 
previous studies determined that Acta2−/− SMCs have increased 
levels of cellular ROS and ERK1/2 signaling (9). To determine 
whether Acta2−/− SMCs are more responsive to exogenous AngII, 
we assessed pRelA levels. Surprisingly, Acta2−/− SMCs show 
activated pRelA in the absence of AngII, whereas WT SMCs do not 
(Figure 3.7 A), and this increased pRelA signaling correlates with 
increased Il6 expression in the Acta2−/− SMCs [data not shown]. 
Furthermore, the Acta2−/− SMCs showed increased sensitivity to 
AngII and prolonged signaling. In the Acta2−/− SMCs, pRelA levels 
increase at 10 nmol/L AngII, whereas pRelA levels do not increase 
in WT SMCs until a 100-fold higher dose of AngII is used 
(1000nmol/L; Figure 3.7 A; [data not shown]). The Acta2−/− SMCs 
are also more sensitive than WT SMCs to exogeneous AngII based 
on intracellular Ca2+ assays (Figure 3.7 B). The Acta2−/− SMCs 
show earlier and more prolonged increases in pRelA levels than 
WT SMCs when exposed to 1 μmol/L AngII [data not shown]. 
Similar to the Acta2−/− aortas, expression of Agtr1a is increased >8-
fold in the Acta2−/− SMCs (Figure 3.7 D). For all cellular studies, 
Agtr1b expression followed the same pattern as Agtr1a but is ≈10-
fold lower (data not shown). 
 
We sought to determine the signaling pathway responsible 
for increased Agtr1a expression and AngII sensitivity in the Acta2−/− 
SMCs. Inhibition of the Agtr1a using losartan effectively blocks the 
increase of pRelA in response to exogenous AngII but does not 
decrease the basal level of pRelA in Acta2−/− SMCs; Il6 expression 
with these treatments correlates with pRelA levels[data not shown]. 
AngII-induced NF-κB activation in SMCs is mediated by 
RhoA/ROCK phosphorylation of Ser536 of RelA (78). Therefore, 
Acta2−/− SMCs were exposed to Clostridium botulinum exoenzyme 
C3 exotoxin to block Rho activation, which blocks AngII-inducible 
pRelA as expected, but does not decrease baseline activation of 
RelA in the Acta2−/− SMCs [data not shown]. ROS is a known 
activator of NF-κB signaling, and we previously found increased 
cellular ROS levels in the Acta2−/− SMCs (9). 
 
Blocking cellular ROS using [N-acetylcysteine (NAC)] 
decreases the baseline pRelA levels in the Acta2−/− SMCs and 
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reduces the sensitivity of these cells to exogenous AngII (Figure 
3.7 C; [data not shown]). NAC treatment also decreases the 
expression of Agtr1a, Il6, and Mmp2 in the mutant SMCs to levels 
similar to WT SMCs (Figure 3.7 D). Finally, pre-treatment of cells 
with NAC abolishes the increase in intracellular calcium in response 
to exogenous AngII in both WT and Acta2−/− SMCs (Figure 3.7 E). 
To confirm that NF-κB signaling is responsible for the 
hypersensitivity of the Acta2−/− SMCs, these cells were treated with 
an NF-κB inhibitor anatabine, which partially blocked 
phosphorylation of RelA (Figure 3.8 A) and also reduced 
expression of Il6, Agtr1a, and Mmp2 to levels similar to WT cells 
(Figure 3.8 B). Helenalin, an inhibitor of NF-κB DNA binding 
activity, which does not affect RelA phosphorylation, also 
significantly blocks expression of Il6, Agtr1a, and Mmp2 [data not 
shown)] (79, 80). In addition, pre-treatment of cells with either 
anatabine or helenalin abolishes the increase in intracellular 
calcium in response to exogenous AngII in both WT and Acta2−/− 
SMCs (Figure 3.8 C). 
 
To identify the source of increased ROS, the expressions of 
the nicotinamide adenine dinucleotide phosphate (NADPH) 
oxidases were assessed, and expressions of Nox4 and p22phox, 
along with a known activator of Nox4, Poldip2, are all significantly 
increased in the Acta2−/− SMCs (Figure 3.8 D) (81, 82). There is no 
significant change in expression of Nox1 or Nox2 [data not shown]. 
Furthermore, a specific inhibitor of Nox4, VCC588646, reduces 
ROS levels in Acta2−/− SMCs and also significantly decreases 
expression of Il6, Mmp2, and Agtr1a (Figure 3.8 E & F) (83). NF-κ
B has been previously shown to directly induce Nox4 
expression,(84) and treatment with helenalin significantly reduces 
expression of Nox4, Poldip2, and p22phox in Acta2−/− SMCs. Taken 
together, our data suggest a feedback loop in which increased ROS 
levels drive NF-κB signaling that increases Nox4, p22phox, and 
Poldip2 expression and ROS accumulation. This feedback loop 
increases expression of Agtr1a leading to increased AngII 
sensitivity in the aortic SMCs.”  
Quoted text reprinted with minimal modification with permission 
from Wolters Kluwer Health (Chen J, Peters AM, Papke CL, Villamizar 
C, Ringuette LJ, Cao JM, Wang S, Ma S, Gong L, Byanova K, Xiong J, 
Zhu MX, Madonna R, Kee P, Geng YJ, Brasier A, Davis EC, Prakash SK, 
Kwartler CS, Milewicz DM. Loss of Smooth Muscle alpha-actin Leads to 
NF-kappaB-Dependent Increased Sensitivity to Angiontensin II in Smooth 
Muscle Cells and Aortic Enlargement. 2017) (11) 
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Figure 3.7 – Increased sensitivity to angiotensin II (AngII) in Acta2−/− 
smooth muscle cells (SMCs) is driven by reactive oxygen species (ROS). A) 
Dose–response curve after 20 min of AngII treatment shows that Acta2−/− 
SMCs have increased baseline phosphorylate RelA (pRelA) that increases 
with exposure to AngII concentrations as low as 10 nmol/L, compared 
with 1000 nmol/L in wild-type (WT) SMCs. B) Immediately after 
stimulation with various doses of AngII, Acta2−/− SMCs have increased 
intracellular Ca2+ levels when compared with WT cells. At least 30 cells 
were measured for each group. C) Treatment with N-acetyl cysteine 
(NAC) reduces baseline pRelA in Acta2−/− SMCs and reduces AngII-induced 
phosphorylation of RelA in both genotypes. D) Acta2−/− SMCs, like the 
aortic tissue, have increased expression of Il6, Agtr1a, and Mmp2. NAC 
treatment significantly reduces expression of all 3 genes but not to WT 
levels. E) Pre-treatment with NAC for 12 h abolishes the increase in 
intracellular Ca2+ levels after stimulation with 0.5 μmol/L AngII in both 
WT and Acta2−/− SMCs. Modified and printed with permission from 
Circulation Research (Chen J, Peters AM, Papke CL, Villamizar C, Ringuette 
LJ, Cao JM, Wang S, Ma S, Gong L, Byanova K, Xiong J, Zhu MX, Madonna 
R, Kee P, Geng YJ, Brasier A, Davis EC, Prakash SK, Kwartler CS, Milewicz 
DM. Loss of Smooth Muscle alpha-actin Leads to NF-kappaB-Dependent 
Increased Sensitivity to Angiontensin II in Smooth Muscle Cells and Aortic 
Enlargement. Circ Res 2017). See reference (11)  ” 
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Figure 3.8 – Inhibition of either nuclear factor (NF)-κB signaling or Nox4 
reduces Agtr1a expression and decreases sensitivity to angiotensin II 
(AngII) in Acta2−/− smooth muscle cells SMCs. A) Helenalin, an inhibitor of 
NF-κB signaling, reduces expression of Il6, Mmp2, and Agtr1a after 6 h of 
treatment. B) Twelve- hour pre-treatment with helenalin or a second NF-
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κB inhibitor anatabine abolishes the increase in intracellular Ca2+ with 0.5 
μmol/L AngII stimulation in both wild-type (WT) and Acta2−/− SMCs. C) 
Acta2−/− SMCs have increased expression of Nox4, Poldip2, and p22phox 
when compared with WT SMCs. D) A specific inhibitor of Nox4, 
VCC588646, reduces reactive oxygen species in Acta2−/− SMCs to WT 
levels. E) VCC588646 treatment reduces expression of Il6, Mmp2, and 
Agtr1a in WT and Acta2−/− SMCs. F) Treatment with the NF-κB inhibitor 
helenalin for 6 h reduces expression of Nox4, Poldip2, and p22phox in 
Acta2−/− SMCs. Modified and reprinted with permission from Circulation 
Research (Chen J, Peters AM, Papke CL, Villamizar C, Ringuette LJ, Cao JM, 
Wang S, Ma S, Gong L, Byanova K, Xiong J, Zhu MX, Madonna R, Kee P, 
Geng YJ, Brasier A, Davis EC, Prakash SK, Kwartler CS, Milewicz DM. Loss 
of Smooth Muscle alpha-actin Leads to NF-kappaB-Dependent Increased 
Sensitivity to Angiontensin II in Smooth Muscle Cells and Aortic 
Enlargement, Circ Res 2017). See reference (11)  . 
 
 
Figure 3.9 – Levels of AngII in Acta2−/− aortas and kidneys are not 
significantly different from WT. Measurements were made at 3 mo of age 
(n=20 aortas per genotype, 4 kidneys per genotype). Modified and 
reprinted with permission from Circulation Research (Chen J, Peters AM, 
Papke CL, Villamizar C, Ringuette LJ, Cao JM, Wang S, Ma S, Gong L, 
Byanova K, Xiong J, Zhu MX, Madonna R, Kee P, Geng YJ, Brasier A, Davis 
EC, Prakash SK, Kwartler CS, Milewicz DM. Loss of Smooth Muscle alpha-
actin Leads to NF-kappaB-Dependent Increased Sensitivity to 
Angiontensin II in Smooth Muscle Cells and Aortic Enlargement. Circ Res 
2017.) See reference (11)   
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3.2.3 L-NAME and NAC in Acta2-/- mice 
Many of the studies in our lab have focused on the role of blood pressure in aortic 
disease. We and others have done numerous studies on mechanical stress and blood 
pressure in mouse models. I specifically discuss how we investigate this model in a hyper 
acute setting in Chapter 4 (52). Others have also shown that mechanically stressing the 
vessels can influence the angiotensin system through a β-arrestin and G-protein mediated 
pathway (85).  
Given these ideas, we decided to significantly increase the biomechanical stress on 
the ascending aorta in the Acta2-/- mice by utilizing a nitric oxide synthase inhibitor, L-NG-
nitroarginine methyl ester (L-NAME), coupled with a high salt diet (8% NaCl in chow, 
Harlan). The regimen made the hypotensive Acta2-/- mice normotensive (Figure 3.10 A) 
(11). With the increase in blood pressure, the studies showed that the increase in 
biomechanical stress in these mice could lead to a significant increase in aortic root size by 
just three months of age compared to the untreated WT and Acta2-/- mice. The ascending 
aorta was also significantly enlarged in the normotensive Acta2-/- mice by 3 months of age 
(Figure 3.10 B & C).  These data show that the forces associated with increased blood 
pressure increase the growth rate of the ascending aorta and aortic root in the Acta2-/- 
mice. 
We initiated a treatment trial with N-acetyl cysteine (NAC), a broad spectrum 
antioxidant, to determine whether reducing ROS could prevent aortic dilation. To better 
observe any decrease in phenotype, we chose to use the Acta2-/- mice treated with L-
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NAME and high salt diet as these mice have accelerated aortic enlargement. Co-treatment 
with L-NAME, high salt diet, and NAC in Acta2-/- mice attenuated the enlargement of the 
ascending aorta when compared with WT aortas, but the aortic root still significantly 
enlarged (Figure 3.10 B & C). These results suggest that ROS plays a greater role in the 
development of ascending aortic enlargement than aortic root enlargement.  
 
Figure 3.10 – A) All tail cuff blood pressure measurements taken in WT mice, Acta2-/- mice 
and Acta2-/- treated over the course of the study. Acta2-/- had significantly lower blood 
pressure than WT mice. L-NAME and a high salt diet were able to increase the blood 
pressure in Acta-/- back to normal. B & C) Treatment with L-NAME and high-salt diet 
significantly increases aortic root dilation at 3 months of age. Treatment with L-NAME, 
NAC, and high salt diet reduces ascending aortic enlargement. Modified and reprinted with 
permission from Circulation Research (Chen J, Peters AM, Papke CL, Villamizar C, Ringuette 
LJ, Cao JM, Wang S, Ma S, Gong L, Byanova K, Xiong J, Zhu MX, Madonna R, Kee P, Geng YJ, 
Brasier A, Davis EC, Prakash SK, Kwartler CS, Milewicz DM. Loss of Smooth Muscle alpha-
actin Leads to NF-kappaB-Dependent Increased Sensitivity to Angiontensin II in Smooth 
Muscle Cells and Aortic Enlargement. Circ Res 2017). See reference (11)  .  
 
3.2.4 Agtra1-/- and Acta2-/- cross 
Since AngII signaling increases superoxide production by activating NADPH oxidases 
in SMCs (86), we crossed the Acta2-/- mice and the Agtr1a-/- mice to determine if ROS are 
increased in the Acta2-/- aortas without AngII signaling from the Agtr1a receptor. Agtr1a-/- 
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mice are hypotensive and have thinner aortic walls than WT, but do not develop 
aneurysms. The aortic tissue is more friable and falls apart easily on dissection, making it 
difficult to work with these mice. I was unable to determine whether aortic dilation was 
decreased or pathologic endpoints were altered in the Acta2-/- Agtr1a-/- double mutant 
mice because the significant hypotension complicated interpretation of the data.  Instead, 
we hypothesized that we would not block the increased ROS signaling in the aorta if the 
Agtr1a receptor was not present, i.e., ROS would still be increased due to the loss of SM α-
actin. Acta2-/- Agtr1a-/- double mutant mice were born in the expected Mendelian ratio, 
despite having lower blood pressures than the Acta2-/- mice (Figure 3.11 C). Both DHE 
staining and lucigenin assays indicate decreased ROS in Acta2-/- Agtr1a-/- mice compare to 
the Acta2-/- mice, suggesting that Agtr1a activity is partially, but not completely, 
responsible for the increased ROS. Importantly, the Acta2-/- Agtr1a-/- aortas still have 
significantly higher ROS levels than WT.  Furthermore, the expression of Il6 and Mmp2 
remains higher in the Acta2-/- Agtr1a-/- double mutant aortas than WT aortas, suggesting 
that pathways other than Agtr1a contribute to the activation of these genes. Expression of 
other renin-angiotensin system components was not significantly different in Acta2-/- 
Agtr1a-/- mice compared with the single mutants (Figure 3.11). 
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Figure 3.11 – Addition of the Agtr1a-/- allele into Acta2-/- mice does not completely prevent 
increased ROS A) frozen DHE staining of aortic sections indicate that ROS levels in the 
aortas of Acta2-/- Agtr1a-/- mice are higher than in WT mice, but lower than in Acta2-/- mice. 
B) NADPH oxidase activity in the Acta2-/- Agtr1a-/- is not different compared to Acta2-/- and 
WT mice. C) Acta2-/- Agtr1a-/- mice have significantly lower systolic blood pressure than 
Acta2-/- mice. D) Expression of Mmp2 is elevated in the Acta2-/- Agtr1a-/- mice compared to 
WT. E) Components of the RAS system appear to not be affected by the loss of Agtr1a. 
Modified and reprinted with permission from Circulation Research (Chen J, Peters AM, 
Papke CL, Villamizar C, Ringuette LJ, Cao JM, Wang S, Ma S, Gong L, Byanova K, Xiong J, Zhu 
MX, Madonna R, Kee P, Geng YJ, Brasier A, Davis EC, Prakash SK, Kwartler CS, Milewicz DM. 
Loss of Smooth Muscle alpha-actin Leads to NF-kappaB-Dependent Increased Sensitivity to 
Angiontensin II in Smooth Muscle Cells and Aortic Enlargement, Circ Res 2017). See 
reference (11) . 
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3.3 Discussion 
I found that NF-κB signaling driven by increased cellular ROS leads to an 
increase in expression of the Agtr1a.  The increased expression of Agtr1a in aortic 
SMCs then leads to activation of AngII-dependent signaling at AngII levels that were 
100 fold lower than that required in WT SMCs in vitro, as assessed by phosphorylation 
of RelA and increased intracellular Ca2+.  Acta2-/- aortas have increased levels of ROS 
and phosphorylated RelA. Increased expression of Agtr1a is also observed.  When the 
Agtr1a receptor is deleted in the Acta2-/- mice, ROS levels remain elevated. This result 
indicates that increases in ROS and downstream molecular changes do not 
completely depend on exogenous AngII signaling through Agtr1a in the Acta2-/- aortic 
SMCs. Exogenous AngII further augments both ROS and NF-κB signaling in the mutant 
cells. In turn, this drives a feedback loop resulting in further increases in ROS and NF-
κB signaling (Figure 3.12). Others groups have shown that when ROS is increased in 
SMCs by overexpression of p22phox, an important subunit for all NADPH oxidases, SMC 
hypertrophy driven by AngII is potentiated, making ROS a potential therapeutic target 
(87). My results indicate that increased cellular ROS in the p22phox-overexpressing 
SMCs could activate NF-κB signaling, increasing the expression of Agtr1a. This ends 
up potentiating AngII signaling in aortic SMCs.   
The Acta2-/- mice develop dilation of the aortic root by 6 months of age. This is 
similar to the aortic root enlargement observed in patients with ACTA2 mutations (70), and 
aortic root dilation is attenuated with losartan, an Agtr1a and Agtr1b blocking agent (ARB). 
However, aortic growth is not completely reversed.  Losartan treatment attenuates pRelA 
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signaling but not through ERK1/2 signaling, suggesting that ERK1/2 activation is driven by 
other pathways.  Knocking out Agtr1a in Acta2-/- mice does not decrease ROS levels to 
those of WT. This suggests that increased ROS and downstream molecular changes are not 
dependent on exogenous AngII signaling through the Agtr1a in the Acta2-/- aortic SMCs in 
vivo. The baseline increase in ROS and/or the pathways driving ERK1/2 signaling may be 
responsible for losartan not completely reversing aortic enlargement. We note that 
significant hypotension in Acta2-/- mice limits forces on the ascending aorta thereby 
attenuating aortic enlargement in this mouse model.  L-NAME and a high salt diet 
increased the blood pressure to levels similar to the WT mice and also significantly 
increased the aorta growth rate. This is consistent with current data that suggests blocking 
nitric oxide (NO) signaling protects the aorta from enlargement in mouse models of 
aneurysms (88), and excessive signaling through a target downstream of NO signaling, type 
I cGMP-dependent protein kinase, can drive thoracic aortic disease (89). Therefore, the 
significantly increased growth rate of the aorta in the Acta2-/- mice after L-NAME treatment 
is due to increased biomechanical stress on the aorta not inhibition of NO-synthase.   
There was a significant increase in elastic lamellae in our mice in addition to an 
increase in SMCs, similar to what is reported with the Eln-/- mice (10). I note that patients 
with ELN hemizygosity show a similar phenotype with supravalvular aortic stenosis and an 
increase in elastic lamellae (90, 91). As stated previously, the number of lamellar units is 
based biomechanical properties (6), and Eln+/- mice are hypertensive.  The increased 
lamellae in these mice are likely due to the increased blood pressure and increased 
biomechanical stress in the wall (92) . The same cannot be said in the hypotensive Acta2-/- 
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mice, but in culture Acta2-/- SMCs are stiffer than WT SMCs (11), so cellular stiffness, rather 
than global wall, stress could be responsible for the increase in lamellar units in the Acta2-/- 
aortas.  Alternatively, the increased elastin lamellae laid down during development could 
be due to increased proliferation of the mutant SMCs.  It is known that Acta2-/- SMCs 
proliferate more rapidly the WT SMCs in vivo and in vitro (9).  Eln+/- SMCs also proliferate 
more rapidly than WT cells (13). Therefore, it is possible that the increased elastin lamellae 
laid down in both mouse models may be a result of the increased proliferative capacity of 
these mutant cells.   
 
Figure 3.12 - Model of dysregulated signaling in Acta2-/- SMCs showing the feedback loop 
linking reactive oxygen species with angiotensin signaling in Acta2-/- SMCs. Reprinted with 
permission from Circulation Research (Chen J, Peters AM, Papke CL, Villamizar C, Ringuette 
LJ, Cao JM, Wang S, Ma S, Gong L, Byanova K, Xiong J, Zhu MX, Madonna R, Kee P, Geng YJ, 
Brasier A, Davis EC, Prakash SK, Kwartler CS, Milewicz DM. Loss of Smooth Muscle alpha-
actin Leads to NF-kappaB-Dependent Increased Sensitivity to Angiontensin II in Smooth 
Muscle Cells and Aortic Enlargement, Circ Res 2017) See reference (11) . 
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The use of an ACEi, captopril, did not inhibit aneurysm formation in these mice. 
Instead it exacerbated the phenotype.  My results differ from studies using other mouse 
models of thoracic aortic disease.   Long-term treatment with captopril reversed aortic 
pathology, aortic growth, and aortic rupture in the Fbln4-/- mouse (65). Additionally, aortic 
disease in the Fbn1C1039G/+ mouse was attenuated by treatment with another ACEi, 
enalapril.  My cellular studies suggest that AngII signaling in SMCs could be increased 
without increased exogenous AngII, which may partially explain the failure of captopril 
treatment to attenuate growth. However, the exacerbation of the aortic enlargement in 
the Acta2-/- mice when these mice were treated with captopril has thus far not been 
explained.  The next chapter (pg. 55) will further explore pharmaceutical manipulation of 
the AngII signaling pathway in another model of thoracic aortic disease.  
We also tested whether the MMP inhibitor, doxycycline, could alter aortic 
pathology in Acta2-/- mice (data not shown). In the hypomorphic Marfan mouse model, 
Fbn1mgR/mgR mice, doxycycline was able to increase their lifespan by about 53 days with 
decreased elastin breaks and levels of Mmp2 and Mmp9 expression (68). Another group 
showed that combining losartan and doxycycline could synergistically prevent thoracic 
aortic aneurysms in Fbn1C1039G/+ mice by down regulating Mmp2 and Mmp9 and restoring 
the structural integrity of the wall (63). However, my results were inconclusive as to 
whether doxycycline decreased aortic enlargement in the Acta2-/- mice.   These studies 
were complicated by the fact that sugar water was used to dissolve the bitter tasting 
doxycycline, and this increased the weight of the treated mice and the size of their aortas.  
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We failed to control for the increased weight by giving the control mice sugar water.  
Furthermore, the study was most likely underpowered to determine differences between 
the groups.   
Next, I hypothesized that development of aortic disease in Acta2-/- mice was 
hindered by hypotension. I showed that making them normotensive with a combination of 
L-NAME and high salt diet drastically accelerated and exacerbated the phenotype over 
time. To further assess the role of biomechanical forces in driving the disease, we 
attempted to use constriction of the thoracic aorta to increase biomechanical forces on the 
ascending aorta (see methods for details) on the Acta2-/- mice (unpublished data). 
However, we were unable to get results from this study because the majority of the Acta2-
/- mice died when they were anesthetized for surgery, including in sham operated mice. 
The high death rate is most likely due to the hypotension in the Acta2-/- mice.  We also had 
increased peri-operative mortality with the TAC procedure in Agtr1a-/- mice, which are also 
hypotensive. I conclude that hypotensive mouse models are unable to survive the stress 
associated with anesthesia and surgery.  
In the end, I was able to show that disrupting SM α-actin sensitizes the aortic SMC 
to exogenous AngII by increasing ROS and NFκB signaling, leading to an increase in the 
expression of Agtr1a. I confirmed this pathway is also activated using pharmacologic 
disruption of SM α-actin filaments in vitro (data not shown) (11). Blocking both ROS 
production with NAC and the AT1R with losartan attenuated aortic growth in the Acta2-/- 
mice.  Based on the signaling pathways identified in these studies, blocking NF-κB signaling 
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should also block aortic growth, and these pathways may also be effective therapeutic 
targets in other patients with disruption in SM α-actin filament formation.   
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Chapter 4 – Pharmacological manipulation of AngII signaling in the TAC mouse model of 
thoracic aortic aneurysm formation 
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4.1 Introduction 
As mentioned earlier, the major risk for thoracic aortic aneurysms and dissections is 
hypertension.   In fact, any condition that increases biomechanical forces on the ascending 
aorta increases the risk for thoracic aortic disease.  Uncontrolled essential hypertension is 
the most concerning risk factor, but other conditions that increase blood pressure also 
predispose to aortic disease such as cocaine or stimulant use, weight lifting, the Valsalva 
maneuver, and congenital defects that constrict the aorta like aortic coarctation (32). 
While Chapter 3 has addressed altered genes that predispose to the disease, hypertension 
can lead to earlier onset thoracic aortic disease in individuals with and without a genetic 
predisposition.  
 I have adopted a mouse model of an acute increase in biomechanical forces to 
assess how increased biomechanical stress leads to aortic enlargement.  A transverse aortic 
constriction (TAC) is created by constricting the aorta between the first two major vessels 
branching off the aorta, the innominate and left common carotid (Section 2.3) (52). The 
model has been used extensively to study pressure-induced cardiac hypertrophy due to 
hypertension or aortic stenosis.  With the acute constriction of the transverse aorta, the 
blood pressure increases proximally on the heart, ascending aorta, and right carotid artery.  
The increased pressures lead to hypertrophy of the left ventricle within two weeks after 
placement of the constriction (93).  Subsequently, the left ventricle dilates, and congestive 
heart failure ensues (66, 94). TAC results may vary due to different surgeons, anesthesia 
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and surgical techniques, and various other factors such as suture migration (94-96). Hence, 
the precise phenotype present in each of these models is open to interpretation. 
Before mice develop heart failure after TAC, increased left ventricular pressure and 
hypertrophy of the heart produces significant increase in biomechanical forces on the 
ascending aortic wall proximal to the site of constriction. Therefore, I used this model to 
study aortic remodeling due to increased biomechanical forces on the ascending aorta and 
limited all analyses to two weeks after constriction so that forces continuously increased 
on the aorta and our results were not complicated by heart failure.  After two weeks, the 
ascending aorta dilates and there is thickening of the medial and adventitial layers in the 
aortic wall.  The medial layer thickens due to widening between the elastin layers without 
evidence of hyperplasia, suggesting SMC hypertrophy.  The adventitial layer increases in 
area and cell density due to accumulation of collagen, myofibroblasts, and macrophages. 
Inflammatory markers are increased, including interlukin-6 (IL6) and monocyte 
chemoattractant protein 1 (MCP-1), and remodeling factors like matrix metalloproteinase 2 
(MMP2) and matrix metalloproteinase 9 (MMP9) also increase in expression (52). 
The pathologic changes associated with aortic remodeling with TAC are similar to 
the pathologic changes in the aorta associated with AngII infusion (28, 30, 57). This 
suggests that AngII signaling may drive the hypertension-associated remodeling.  We 
hypothesized that utilizing an ARB, losartan, would alter the response and prevent the 
observed pathologic changes and aortic enlargement. The administration of losartan 3 days 
prior to TAC and for two weeks post operatively eliminated the vascular inflammatory 
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response, including the macrophage accumulation. Losartan partially rescues the TAC-
induced adventitial hyperplasia, collagen accumulation, and ascending aortic dilatation.  
Therefore, I concluded that signaling through the AT1R was completely responsible for the 
vascular inflammation and partially responsible for the TAC-induced aortic remodeling.  
At the outset of these studies, the signaling downstream of AT1R was the interest. 
It is well established that there are different intracellular pathways associated with the 
AT1R, only some of which are ligand-dependent (97). I was specifically interested in the 
ligand independent pathways that had been investigated in the heart. Known to play a part 
in load induced hypertrophy, it was shown in vivo and in vitro that stimulation of the AT1R 
independently of AngII leads to translocation of G-proteins into the cytosol via Janus kinase 
2. This activation was inhibited by another ARB, candesartan (64). Later, it was shown ex 
vivo that mechanical stretch mediates a confirmation change in β-arrestin, driving signaling 
consistent with ligand mediated AT1R signaling. Hearts from mice lacking β-arrestin or the 
AT1R did not respond to the mechanical stress (85). The ligand-independent activation of 
AT1R in vascular SMCs has also been investigated. Mechanical signaling of the Agtr1a to 
activate SMC’s in mesenteric and renal arteries did not rely on ion channels TRPC6 or 
KCNQ3, 4, or 5 for SMC (98). However, in FbnC1039G/+ mice, studies suggested that β-arrestin 
contributed to thoracic aortic aneurysm formation in Marfan syndrome (99). Hence, we 
wanted to investigate the ligand independent activation of the AT1R in our TAC model. 
At the initiation of these studies, we sought to confirm whether the remodeling is 
due to an increase in circulating AngII levels or if ligand-independent signaling is a more 
important driver of disease. To test this hypothesis, we administrated an ACE inhibitor to 
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block conversion of angiotensin I to angiotensin II to see if it prevented hyper-acute aortic 
remodeling in our TAC model.  
 
4.2 Results 
4.2.1 Treatment with captopril fails to rescue remodeling associated with TAC   
Wildtype C57BL6/J male mice (12 weeks of age) underwent TAC or sham surgeries 
with or without treatment with either losartan or captopril to determine if captopril could 
prevent pathologic remodeling as effectively as losartan. All treatments were started ~72 
hours prior to surgery with losartan and captopril given via drinking water at 600 mg/L or 
75 mg/L, respectively. Initial experiments showed a significant decrease in survival with 
captopril treatment (Figure 4.1 A) despite the fact that the losartan mice were significantly 
more constricted than the captopril treated group (Figure 4.1 B). Necropsy results from our 
preliminary study showed multiple deaths due to aortic rupture or dissection in the 
ascending aorta.  I first noted that only mice treated with captopril were acutely dying 
post-operatively for no apparent reason. Prior TAC studies performed by this surgeon did 
not result in similar deaths, so I began to investigate whether and how captopril might be 
causing death. I performed surgery on a second group of mice and monitored survival rates 
closely, with necropsy performed on any non-surviving mice. Closer examination indicated 
that only mice treated with captopril were acutely dying outside of what we considered the 
perioperative window. Therefore, I began to monitor the mice more closely in the second 
preliminary group and the monitored survival rates after post-op day five were consistent 
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with our first group and necropsies were routinely performed. Two mice treated with 
captopril following TAC specifically stood out. Prior to echocardiography on day 14, one 
mouse exhibited behaviors consistent with significant discomfort and pain.  Necropsy 
revealed an intramural hematoma in this mouse (Figure 4.1 C). Another visibly healthy 
mouse acutely died after post-op day five, and gross examination of the ascending aorta 
indicated a dissection that started in the ascending aorta. Histologic examination of the 
same mouse indicated that blood was present in the vessel wall near the pulmonary artery 
(Figure 4.1 D & E).  
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Figure 4.1 – A) The survival curve after TAC and treatment with either losartan or captopril. 
Only mice treated with captopril died after TAC. B) The increased deaths of the mice 
treatment with captopril were not due to increased constriction as measured by 
RCCA/LCCA ratio. C) Prior to echocardiography on day 14, this mouse exhibited behaviors 
consistent with significant discomfort. After necropsy, thorough cleaning of the aorta 
revealed and intramural hematoma (red arrow). D) Gross examination of the ascending 
aorta of another mouse who on necropsy who died acutely indicated a dissection that 
started in the ascending aorta (red arrow). Histologic examination of the same mouse, (F) 
indicated that blood was present in the vessel wall (red arrow) near the pulmonary artery. 
* indicates p≤0.05. 
 
These initial experiments were repeated by a different surgeon performing the TAC. 
There was a significant increase in the ascending aorta and aortic root diameter between 
the WT sham controls and WT TAC mice (Figure 4.2 A, B, & C). As in my previous study, 
aortic growth was attenuated by losartan treatment compared to untreated TAC mice in 
the ascending aorta and aortic root. Captopril treatment, on the other hand, was unable to 
attenuate the increase in size of the ascending aorta or aortic root in these mice to the 
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same extent as the losartan treatment.  In contrast to the previous studies, none of the 
captopril treated mice died after the five day peri-operative period.  
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Figure 4.2 – A) In our third set of studies, echoes from the four different groups were 
obtained in our WT sham, TAC, TAC+captopril, and TAC+losartan treated groups. The 
approximate locations of the measurements are indicated in the sham image. B & C) The 
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increase in the ascending aorta and in the aortic root size was significant in the untreated 
TAC mouse compared to sham. Losartan was able to attenuate the increase in size as 
previously observed. However, TAC mice treated with captopril was not attenuated. D) As 
previously, the level of constriction was verified via Doppler flow studies indicating 
successful constriction in all TAC mice. E) Successful constriction in TAC mice were also 
verified by measuring blood flow across the constriction in the transverse aorta. * indicates 
p≤0.05, ** indicates p≤0.01, *** indicates p≤0.001, and **** indicates p≤0.0001. (Andrew 
M. Peters, Zhen Zhou, Jiyuan Chen, Alexandra Janda, Corey L. Reynolds, Shao-Qing Kuang, 
Shanzhi Wang, Siddharth Prakash, GenTAC Consortium, Callie S. Kwartler, Dianna M. 
Milewicz Pharmacologic Manipulation of the Angiotensin System Affects Aortic Remodeling 
and Aneurysm Development: Cautions for Clinical Practice, Submitted 2017) See reference 
(77). 
 
The level of constriction was accessed by comparing the ratio of Doppler velocities 
between the right common carotid artery (RCCA) and the left common carotid artery 
(LCCA) (RCCA/LCCA). In my original studies, a successful constriction was considered a ratio 
between 5-10 which was also consistent with what was seen in literature and our 
preliminary studies (52, 66). It is important to note that the ratios in the constricted groups 
were consistently above 10 without a decrease in survival rates (Figure 4.2 D), which was 
higher than the ratio in our previous studies (Figure 4.1 B). We also assessed blood flow 
across the aortic constriction in these mice as this has been reported to be another method 
to assess the level of constriction (100). It was significantly elevated in all the TAC groups 
compared to the sham, and there was no significant difference between the TAC groups 
(Figure 4.2 E).  
Histologic analysis of the TAC mice showed that the increase in vascular and 
adventitial area was similar between the losartan and captopril treated groups (Figure 4.3 
A, B, & C). These results reflected the observations in my first study, but my earlier 
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histopathologic measurements were too underpowered to indicate a significant different 
between the medial area in these groups (data not shown). The adventitial cell density 
decreased significantly in the captopril treated group compared to the non-treated TAC 
group and sham control (Figure 4.3 D), and the medial cell density significantly decreased 
in both TAC and TAC + Captopril groups compared to the sham controls (Figure 4.3 E). 
Additionally, inflammatory markers including IL6, MCP-1, MMP2, and MMP9 remained 
elevated under captopril treatment compared to WT sham (data not shown), but this was 
difficult to assess given these markers were nearly undetectable in my WT sham cohort. 
The changes in the structure of the aortic wall were consistent with our previous TAC 
studies with an increased distance between the elastic lamellae increased number of Mac-
2 positive cells in untreated and captopril treated TAC mice (Figure 4.4 A). The increase in 
distance between the lamellae coupled with the significant decrease in medial cell density 
could indicate that there is significant SMC hypertrophy. The expansion of the adventitia 
also appeared to consist largely of proteoglycans along with inflammatory cells. In the 
media, we verified that there was a significant increase in elastin breaks in the mice 
undergoing TAC that was not attenuated with captopril treatment (Figure 4.4 B). We also 
observed a significant increase in the proteoglycans in the medial layer in addition to what 
we observed in the adventitia (Figure 4.4 C). Cell counting confirmed that there was a 
significant increase in inflammatory cells that was not reversed with captopril treatment 
(Figure 4.4 D). 
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Figure 4.3 – A, B, & C) H&E stains showing that captopril did not alter the increase in 
vascular or adventitial area. D) Treatment with captopril in TAC mice increased adventitial 
cell density compare to both the sham and TAC controls. E) Medial cell density was also 
significantly decreased in the TAC and TAC + captopril mice compared to sham controls. * 
indicates p≤0.05, ** indicates p≤0.01, *** indicates p≤0.001, and **** indicates p≤0.0001. 
(Andrew M. Peters, Zhen Zhou, Jiyuan Chen, Alexandra Janda, Corey L. Reynolds, Shao-Qing 
Kuang, Shanzhi Wang, Siddharth Prakash, GenTAC Consortium, Callie S. Kwartler, Dianna 
M. Milewicz Pharmacologic Manipulation of the Angiotensin System Affects Aortic 
Remodeling and Aneurysm Development: Cautions for Clinical Practice, Submitted 2017) 
See reference (77). 
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Figure 4.4 – A) Movat stains (top) show the changes in the structure of the aortic wall were 
consistent with my previous TAC studies showing an increased distance between the elastic 
lamellae increased number of Mac-2 positive staining cells in untreated and treated TAC 
mice. B) There was significant increase in elastin breaks in the mice undergoing TAC, and C) 
increase in the proteoglycan in the medial layer. D) Cell counting confirmed that there was 
a significant increase in inflammatory cells that was not reversed with captopril treatment. 
* indicates p≤0.05, ** indicates p≤0.01, and *** indicates p≤0.001. (Andrew M. Peters, 
Zhen Zhou, Jiyuan Chen, Alexandra Janda, Corey L. Reynolds, Shao-Qing Kuang, Shanzhi 
Wang, Siddharth Prakash, GenTAC Consortium, Callie S. Kwartler, Dianna M. Milewicz 
Pharmacologic Manipulation of the Angiotensin System Affects Aortic Remodeling and 
Aneurysm Development: Cautions for Clinical Practice, Submitted 2017) See reference (77). 
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4.2.2 C21 is beneficial in biomechanical stress model 
There are additional receptors involved in that angiotensin system other than the 
ligand dependent or independent signaling of the AT1R (See section 1.3, pg. 10). Therefore, 
I sought to characterize the role of the AT2R and Mas receptor in the captopril treated TAC 
mice by treating with agonists for these receptors: compound 21 (C21) is an agonist for the 
AT2R while AVE0991 is an agonist for the Mas receptor.  I focused on the physiologic 
changes associated with treatment. Ultrasound examination of the ascending aorta and the 
aortic root again showed a significant increase in aortic size in the ascending aorta, which 
was not attenuated with captopril.  Co-treatment with C21 was able to eliminate the 
increase in the ascending aortic diameter, but it only attenuated the increase in size in the 
aortic root. Meanwhile co-treatment with AVE0991 with captopril had no effect on the 
ascending aorta or aortic root compared to untreated or captopril treated mice and 
remained significantly elevated compared to mice treated with both captopril and C21 
(Figure 4.5 A & B).  As with previous studies, I verified the level of constriction using the 
ratio between the left and right carotid (RCCA/LCCA) and flow across the constriction site 
(Figure 4.6 C & D).  
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Figure 4.5 – A & B) Echoes of the ascending aorta and the aortic root again showed a 
significant increase in the ascending aorta size which was not attenuated with captopril. 
Co-treatment with C21 was able to eliminate the change in the ascending aorta and 
attenuate it in the root. Meanwhile co-treatment with AVE0991 and captopril had no effect 
compared to untreated mice.  C & D) We verified that the constriction in the untreated and 
treated mice were similar between groups using two methods.  * indicates p≤0.05, ** 
indicates p≤0.01, *** indicates p≤0.001, and **** indicates p≤0.0001. (Andrew M. Peters, 
Zhen Zhou, Jiyuan Chen, Alexandra Janda, Corey L. Reynolds, Shao-Qing Kuang, Shanzhi 
Wang, Siddharth Prakash, GenTAC Consortium, Callie S. Kwartler, Dianna M. Milewicz 
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Pharmacologic Manipulation of the Angiotensin System Affects Aortic Remodeling and 
Aneurysm Development: Cautions for Clinical Practice, Submitted 2017) See reference (77). 
 
 
In our original publication on aortic remodeling with TAC, we did not assess blood 
pressure (52). For the studies reported here, I assessed blood pressure and pulse pressure 
in the ascending aorta by inserting a catheter into the right carotid artery and advancing it 
to the ascending aorta. There was a significant increase in systolic blood pressure in the 
TAC mice, and systolic blood pressure was significantly decreased in both treatment 
groups.  In contrast, the diastolic blood pressure was not different between the TAC and 
sham group.  However, the losartan and captopril treated mice both had significantly lower 
diastolic blood pressure (DBP) compared to sham and TAC controls in the ascending aorta 
(Figures 4.6 A & B). There was no difference in pulse pressure between any of the treated 
or untreated in mice that underwent TAC (Figure 4.6 C), which was interesting since cyclic 
strain has been directly correlated with vascular disease in the carotid arteries (101).  
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Figure 4.6 – With an intraluminal catheter, we directly measured the A) systolic and B) 
diastolic blood pressure in the groups. C) Pulse pressure was then calculated. All TAC mice 
had significantly increased systolic blood pressure, but the blood pressure in mice treated 
with losartan and captopril were significantly lower. The losartan and captopril treated 
mice also had significantly decreased diastolic blood pressure compared to both sham and 
untreated TAC mice, but the pulse pressure was consistent in all mice treated with TAC. * 
indicates p≤0.05 and ** indicates p≤0.01. (Andrew M. Peters, Zhen Zhou, Jiyuan Chen, 
Alexandra Janda, Corey L. Reynolds, Shao-Qing Kuang, Shanzhi Wang, Siddharth Prakash, 
GenTAC Consortium, Callie S. Kwartler, Dianna M. Milewicz Pharmacologic Manipulation of 
the Angiotensin System Affects Aortic Remodeling and Aneurysm Development: Cautions 
for Clinical Practice, Submitted 2017) See reference (77). 
 
 
 Lastly, mice undergoing TAC were treated with C21 alone, which was able to 
decrease the ascending aorta similar to the captopril and C21 treated mice but not the 
aortic root when compared to the untreated TAC mice (Figure 4.7).  As expected, direct 
measurement of the systolic blood pressure (SBP) in the ascending aorta and aortic root 
was significantly increased in all mice that underwent TAC. Any combination of the 
pharmaceutical agents was capable of decreasing the SBP however, all remained elevated 
compared to WT sham mice. While diastolic blood pressure (DBP) remained normal in the 
untreated TAC mice, all treated TAC mice had a significant decrease in DBP compared to 
sham and control mice (Figure 4.8). These results are consistent with our earlier study, 
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which indicated TAC mice had increased pulse pressure with or without any 
pharmaceutical manipulation. 
 
Figure 4.7 – Ultrasound assesments of the aortic root and ascending aortic diameters in WT 
sham, TAC, TAC + losartan, TAC + captopril, TAC + captopril + AVE0991, TAC + captopril+ 
C21, and TAC + C21. The number of observations for each group is listed at the bottom of 
each graph, and significant p values are listed above. As expected TAC mice had an increase 
in the size of the aortic root and ascending aorta compared to sham mice, and losartan was 
able to attenuate these changes. Captopril alone was not able to attenuate the increase, 
and the combination with AVE0991 did not show any significant changes compared to the 
untreated mice. Captopril in combination with C21 was able to significantly decrease the 
increase in aortic size.  Alone, C21 was only able to decrease the ascending aorta when 
compared to the untreated TAC mice. (Andrew M. Peters, Zhen Zhou, Jiyuan Chen, 
Alexandra Janda, Corey L. Reynolds, Shao-Qing Kuang, Shanzhi Wang, Siddharth Prakash, 
GenTAC Consortium, Callie S. Kwartler, Dianna M. Milewicz Pharmacologic Manipulation of 
the Angiotensin System Affects Aortic Remodeling and Aneurysm Development: Cautions 
for Clinical Practice, Submitted 2017) See reference (77). 
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Figure 4.8 – As expected, direct measurement of the systolic blood pressure (SBP) in the 
ascending aorta and aortic root was significantly increased in all mice that underwent TAC. 
Any combination of the pharmaceutical agents was capable of decreasing the SBP, but they 
all remained elevated compared to WT sham mice. While diastolic blood pressure (DBP) 
remained normal in the untreated TAC mice, all treated TAC mice had a significant 
decrease in DBP compared to sham and control mice. (Andrew M. Peters, Zhen Zhou, 
Jiyuan Chen, Alexandra Janda, Corey L. Reynolds, Shao-Qing Kuang, Shanzhi Wang, 
Siddharth Prakash, GenTAC Consortium, Callie S. Kwartler, Dianna M. Milewicz 
Pharmacologic Manipulation of the Angiotensin System Affects Aortic Remodeling and 
Aneurysm Development: Cautions for Clinical Practice, Submitted 2017) See reference (77). 
 
 
 The aortic pathology was also assessed in these aortas from animals treated with 
losartan, captopril, and captopril plus the agonists.   The pathologic changes in the 
adventitia in the losartan and captopril treatment were consistent with what was 
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previously shown (Figure 4.3). Interestingly, there appeared to be little change in the 
adventitia with co-treatment of captopril and C21 or C21 alone.  However, treatment with 
captopril and AVE0991 decreased both the medial and adventitial area with an increase in 
adventitial cell density and decrease in medial cell density (Figure 4.9). There was 
significant proteoglycan deposition in the adventitia in all groups.  
Next, vascular inflammation was assessed by Mac-2 staining for macrophages in the 
adventitia. TAC causes significant increases macrophage positive cells in the adventitia, and 
losartan completely blocks the accumulation of Mac-2 positive cells in the adventitia. 
However, captopril and co-treatment with C21 or C21 alone do not appear to decrease this 
accumulation of Mac-2 cells in the adventitia.  In contrast, co-treatment of captopril and 
AVE0991 completely eliminate Mac-2 positive cells the inflammatory response in the 
adventitia (Figure 4.11). Sirius red staining for collagen deposition indicated a significant 
increase in the adventitial fibrotic response with TAC. This response was attenuated with 
losartan but remained elevated with captopril treatment and C21 with and without 
captopril. Interestingly, AVE0991 treatment with captopril significantly decreases the 
amount of collagen in the adventitia (Figure 4.12).  
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Figure 4.9 – Preliminary H&E stains (n=2) confirming what was previously observed in all of 
our earlier published and unpublished studies. TAC increased medial and adventitial 
thickening, and losartan treatment was able to attenuate it. Losartan was able to attenuate 
the changes. While captopril attenuated the changes in the medial layer, it appeared to not 
do so in the adventitial layer, and the pathologic changes in the adventitia observed in 
these mice were consistent with what was previously shown. There appeared to be little 
change with co-treatment of captopril and C21 or C21 alone, but treatment with captopril 
and AVE0991 appeared to significantly both medial and adventitial area. There also 
appeared to be an increase in adventitial cell density. Note that p values not calculated. 
(Andrew M. Peters, Zhen Zhou, Jiyuan Chen, Alexandra Janda, Corey L. Reynolds, Shao-Qing 
Kuang, Shanzhi Wang, Siddharth Prakash, GenTAC Consortium, Callie S. Kwartler, Dianna 
M. Milewicz Pharmacologic Manipulation of the Angiotensin System Affects Aortic 
Remodeling and Aneurysm Development: Cautions for Clinical Practice, Submitted 2017) 
See reference (77). 
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Figure 4.10 – Movat staining (n=2) shows increased proteoglycan deposition in the 
adventitial layer. There was an increase in the distance between the elastic lamellae in TAC 
mice, and significant proteoglycan deposition in the adventitia. These observations 
appeared slightly attenuated in the losartan treated mice, but was absent in the captopril 
and AVE0991 treated mice. While the adventitia appears larger compared to the WT sham 
controls, there appears to be less proteoglycan deposition and more cells in the wall. Note 
that p values not calculated. (Andrew M. Peters, Zhen Zhou, Jiyuan Chen, Alexandra Janda, 
Corey L. Reynolds, Shao-Qing Kuang, Shanzhi Wang, Siddharth Prakash, GenTAC 
Consortium, Callie S. Kwartler, Dianna M. Milewicz Pharmacologic Manipulation of the 
Angiotensin System Affects Aortic Remodeling and Aneurysm Development: Cautions for 
Clinical Practice, Submitted 2017) See reference (77). 
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Figure 4.11 – Mac-2 staining of the aortas (n=2). TAC significant increases macrophage 
positive cells in the adventitia, and losartan attenuates it. Captopril and co-treatment with 
C21 or C21 alone do not appear to decrease this inflammatory response. Co-treatment of 
captopril and AVE0991 appeared to completely eliminate the inflammatory response in the 
adventitia. Note that p values not calculated. (Andrew M. Peters, Zhen Zhou, Jiyuan Chen, 
Alexandra Janda, Corey L. Reynolds, Shao-Qing Kuang, Shanzhi Wang, Siddharth Prakash, 
GenTAC Consortium, Callie S. Kwartler, Dianna M. Milewicz Pharmacologic Manipulation of 
the Angiotensin System Affects Aortic Remodeling and Aneurysm Development: Cautions 
for Clinical Practice, Submitted 2017) See reference (77). 
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Figure 4.12 – Sirius red staining (n=2) in the cells indicated a significant increase in the 
adventitial fibrotic response, and it was attenuated with losartan but remained elevated 
with captopril treatment. It appears to be slight decreased with C21 with and without 
captopril. AVE0991 treatment with captopril and TAC significantly decrease the amount of 
collagen in the adventitia. Note the absence of p values. (Andrew M. Peters, Zhen Zhou, 
Jiyuan Chen, Alexandra Janda, Corey L. Reynolds, Shao-Qing Kuang, Shanzhi Wang, 
Siddharth Prakash, GenTAC Consortium, Callie S. Kwartler, Dianna M. Milewicz 
Pharmacologic Manipulation of the Angiotensin System Affects Aortic Remodeling and 
Aneurysm Development: Cautions for Clinical Practice, Submitted 2017) See reference (77). 
 
4.2.3 Knock out of Agtr1a fails to alter vascular inflammation 
 Given the effectiveness of losartan in previous studies (61, 65), I set out early to try 
to perform TAC in Agtr1a-/- mice. We expected results similar to those observed in 
pharmaceutically treated mice in Agtr1a-/- mice. The Agtr1a-/- mice are hypotensive 
compared to WT controls (Figure 4.13). My early results indicated a significantly decreased 
peri-operative survival rate making my study difficult. Because of my concerns regarding 
possible flaws in my original study, this was repeated with two different surgeons.  After 
the peri-operative period, surviving Agtr1a-/- mice were not significantly different than the 
WT untreated TAC mice. Vascular and adventitial area remained elevated in WT and 
Agtr1a-/- untreated mice. Investigation of inflammatory markers such as Mac-2 indicated 
that inflammation was attenuated in Agtr1a-/- TAC mice (Figure 4.14). Therefore, we 
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investigated the difference between the WT and Agtr1a-/- mice. Agtr1a-/- mice have 
decreased medial area compared to WT mice, but the medial area is significantly increased 
compared to Agtra1-/- mice after TAC. Vascular and adventitial expansion are still present in 
Agtr1a-/- TAC mice compared with both WT and Agtr1a-/- sham controls (Figure 4.15). TAC 
Agtr1a-/- mice show increased distance between the elastic lamellae, but Agtr1a-/- mice 
appear to have more elastic lamellae, and early results in other studies have indicated that 
they are less developed.    
 
Figure 4.13 – SBP and DBP measurement taking in WT and Agtra1-/- mice to verify their 
decreased blood pressure. All measurements taken by tail cuff following the protocol 
previously mentioned (Section 2.5). ** indicates p≤0.01.  
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Figure 4.14 – My preliminary studies in mice deficient in Agtr1a did not have the same 
effect as while type mice treated with losartan. A, B, & C) Vascular and adventitial area 
remain elevated in WT and Agtr1a-/- treated mice. D) While inflammation appeared to be 
attenuated in these mice, the number of Mac-2 positive cells was only attenuated in 
Agtr1a-/- mice.  
 
 
A 
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Figure 4.15 – A, B, & C) Agtr1a-/- mice have decreased medial area compared to WT mice, 
but the medial area is significantly increased compared to Agtra1-/- mice after TAC. C & D) 
Significant vascular and adventitial expansion is still present in Agtr1a-/- mice compare to 
both sham controls. E) There is a significant increase in SMCs in the media under control 
conditions. F & G) When analyzed by weight, the ascending aorta is significantly lower in 
the sham mice compared to WT sham, but there is no difference between the two in the 
aortic root.  
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Figure 4.16 – Significant adventitial expansion remains in the TAC Agtr1a-/- compared to 
WT and Agtr1a-/- mice who underwent sham surgery. TAC Agtr1a-/- mice show increased 
distance between the elastic lamellae, but Agtr1a-/- mice appear to have more elastic 
lamellae and early results appear less developed.   
 
4.3 Discussion 
 We have previously shown that signaling through the AT1R is responsible for a 
significant portion of the aortic remodeling that occurs with TAC.  A prominent component 
of TAC-induced aortic remodeling is vascular inflammation characterized by increased Il6 
and Mcp1 expression and recruitment of macrophages to the adventitia, and these 
changes are completely blocked when signaling through the AT1R is prevented by 
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treatment with losartan.  Other changes are only partially blocked, including ascending 
aortic dilatation, adventitial cellular hyperplasia and collagen accumulation. I initially 
hypothesized that the AT1R activation was not due to increased AngII in aortic tissue, but 
rather mechanical stretch activation of the AT1R, which has been described in 
cardiomyocytes and SMCs (64, 85, 98, 99).  Furthermore, it has been shown that inverse 
agonists of the AT1R can block this activation of the AT1R (102).  Although losartan is not 
an AT1R inverse agonist, EXP3174, an active metabolite of losartan, can act as an inverse 
agonist in the inositol phosphate (IP) production assay based on studies involving a 
constitutively active AT1-N111G mutant (103). To begin to investigate whether AT1R 
activation with TAC-induced aortic remodeling was ligand independent, I blocked the 
production of AngII using captopril. Indeed, captopril did not block the aortic dilatation and 
vascular remodeling associated with TAC, supporting the conclusion that the AT1R 
activation in SMC with TAC is ligand independent. At the same time, the initial experiments 
suggested that captopril had a negative effect on aortic remodeling, leading to increased 
deaths due to aortic rupture.   
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Figure 4.17 – Working model indicating my points of interest in the angiotensin system. 
The questions remaining are the influence of the AT2R and Mas receptor in our hyper-
acute model specifically in the ascending aorta and how they could modulate the ligand 
independent signaling. 
 
 I sought to determine the role of signaling through other receptors in the 
angiotensin system with TAC when all AngII signaling is blocked and aortic remodeling is 
dependent on mechanical stimulation.  AT2R receptors are present in vascular SMCs, and 
have been reported to comprise approximately 30% of the AngII receptors in the rat aorta 
(104).  It is feasible that AT1R activation proceeds unchecked when all the receptors are 
blocked but selective activation of AT2R could block aortic enlargement to the same extent 
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as losartan treatment alone.  As stated above (Section 1.3), the AT2R has been known to 
counter the effects of the AT1R downstream in multiple systems. In the vascular SMCs, the 
AT1R increases proliferation, fibrosis, MMP2, and MMP9 expression (52), while the AT2R 
decreases proliferation, fibrosis, and MMP9 and MMP2 expression (48, 105).  However, in 
some models the AT2R has been thought to affect smooth muscle cell apoptosis (53, 54) 
Another ACEi, enalapril, was used to reinforce the importance of the AT2 receptor. 
A cross between the FblnC1039G/+ with mice deficient in AT2R, Agtr2-/y (106), actually 
increased aneurysm formation and made losartan less effective (48). Their results indicated 
the AT2R decreases pERK signaling, cell proliferation, fibrosis, and MMP9 signaling. Their 
results were reinforced by other labs, which showed that antagonists of the AT2R are 
detrimental in abdominal aortic models. In ApoE-/- mice infused with AngII, the antagonist 
of the AT2R, PD123319, leads to an increase in atherosclerosis and AngII induced vascular 
pathology (107). However, they later showed PD123319 could work by an AT2R 
independent mechanism, which complicates interpretation of their results (108). Still, the 
independent beneficial effects of the AT2R could possibly explain why captopril was not 
just ineffective but detrimental.  
 Ang1-7 is a peptide mainly generated from AngII by angiotensin converting enzyme 
2 (ACE2), but which can also be made from AngI via neutral endopeptidase activity.  Ang1-7 
binds to the G protein-coupled receptor Mas. In SMCs, Mas receptor signaling is considered 
an antagonist of AngII signaling. Mas receptor signaling is vasodilatory and blocks 
hypertrophy and migration of SMCs.  Importantly, Ang1-7 blocks the pro-inflammatory 
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response triggered by AngII in primary human SMCs in culture by blocking NF-κB signaling 
and inducible nitric oxide synthase induction. With exposure to AngII, SMCs activate NF-κB 
signaling, and Ang1-7 markedly inhibits this activation and the associated inflammatory 
changes (109). Specifically, Ang1-7 suppresses superoxide anion levels and NADPH oxidase 
activity that occurs in SMCs with exposure to AngII (110), but does not have these effects 
on SMCs in the absence of AngII exposure.  In our studies of TAC-induced aortic remodeling 
and blocking angiotensin signaling through the major receptors, selective activation of the 
Mas receptor agonist completely blocked vascular inflammation based on decreased Il6 
and Mcp1 expression and lack of macrophage accumulation in the adventitia.  At the same 
time, aortic enlargement was not rescued and the aortic pathology was adversely affected. 
The Mas agonist prevented SMC hypertrophy and instead caused SMC loss in the aortic 
media and decreased fibrosis in the adventitial layer. The loss of SMCs is in contrast to a 
protective role of the Mas receptor in other cells types.   
Ang1-7 has been studied extensively in multiple systems. In the kidney, its 
activation has been associated with decreased matrix protein production and improved 
renal function and its inhibition associated with increased collagen deposition, TGF-β, 
Smad2/3, ERK1/2, and NFKβ (55). In rat models, Ang 1-7 was shown to improve heart 
function by reducing cardiomyocyte hypertrophy, fibrosis and inflammatory cell infiltration 
with short term administration. In the cerebrovasculature, in a study of intracerebral 
hemorrhagic stroke with C57BL/6 mice, it was shown to modulate NF-κB signaling by 
decreasing TNF-α, MCP-1, and IL-8 (111). Of interest to me, another group utilized mice 
deficient in ACE2, Ace2-/y (112) and the AngII infusion model to study the thoracic aorta. 
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They were able to find ACE2 deficiency worsened the AngII mediated inflammation model 
with enhanced AKT phosphorylation, increased ERK1/2, and increased endothelial nitric 
oxide synthase. These results could be reversed with an ARB, irbesartan, that prevented 
inflammation by suppressing the Akt-ERK-eNOS signaling pathway (113).    Therefore, the 
loss of SMCs and other adverse pathologic changes with TAC when the Mas receptor is 
activated suggests that ROS generation with TAC plays a protective role in aortic SMCs.   
 While our focus is on the angiotensin system, we must remember the kinin system 
also influences the vascular disease. Kininogen is metabolized by kallikrein into bradykinin. 
Bradykinin, a fundamental part of the kinin system, has been a well-established vasodilator 
helping to control blood pressure. It has also been associated with increased vasodilation, 
vascular permeability, inflammation, and pain.  ACE is one of the major vasopeptidases 
regulating bradykinin signaling as it metabolizes bradykinin into its inactive forms. 
Subsequently, ACEi use has been shown to increase nitric oxide and vasorelaxation (114). 
Hence, the kinin system may play a role in the results I observed with captopril. While 
inhibiting both AT1R and AT2R, we may have left bradykinin uninhibited resulting in our 
increased inflammation observed with captopril treated mice compared to losartan treated 
mice.  
Finally, I sought to determine how TAC-induced aortic remodeling would occur with 
loss of the AT1R.  These studies were complicated by the fact that the Agtr1a-/- mice are 
significantly hypotensive and appear underdeveloped ascending aortas. Interestingly 
deletion of Agtr1a-/- in mice has been associated with a variety of factors including 
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increased life expectancy (115, 116), but diminished growth, vascular thickening, and 
atrophy of the inner renal medulla (117).  Despite these issues with the aorta, it was still 
surprising that TAC induced medial wall thickening, adventitial thickening, and vascular 
inflammation were present in the Agtr1a-/- mice. We expected our results to be similar to 
the mice treated with losartan. Based on the pharmacologic manipulation of aortic 
remodeling with TAC, these changes are proposed to be in part due to ligand independent 
activation of AT1R.  Despite this conclusion, it is clear that mechanical forces are still able 
to cause remodeling in the absence of the Agtr1a.  It is notable that not all TAC-induced 
remodeling is blocked by losartan (52), but the influence of deleting a gene in a highly 
variable system is difficult to predict. In such a dynamic system, there is no guarantee that 
another signaling pathway does not become more dominant or compensates for the loss of 
the Agtr1a receptor. Humans only have one isoform of the AT1R, but mice have two, and in 
the kidney the absence of once can be compensated by the other isoform (117). In this 
model, Agtr1b is still present, and it is yet unknown how it might affect the cell types in the 
ascending aorta and whether it can compensate for the loss of Agtr1a. Others have found 
Agtr1b to be more mechanosensitive in vascular SMC myogenic vasoconstriction (118). This 
model would need to be studied more extensively to verify the role of Agtr1b in TAC-
induced remodeling of Agtr1a-/- mice.   
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Chapter 5 – Discussion and Conclusions 
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5.1 Introduction 
I hypothesized that angiotensin II signaling through the AT1R contributes to thoracic 
aortic aneurysm formation in multiple model systems of disease, but that blocking related 
receptors in addition to the AT1R, such as the AT2R and Mas receptor, may have negative 
consequences. In the Acta2-/- mouse model, I found an increased sensitivity of cells to AT1R 
signaling without exogenous AngII was due to increased ROS and NF-ΚB signaling. Acta2-/- 
mice develop dilated aortas over time, and the dilation is partially blocked with an ARB, 
losartan, but blocking the formation of the ligand with an ACEi, captopril, was insufficient 
to attenuate disease. In TAC, I again found that ARB treatment attenuated the physiologic 
and pathophysiologic changes I observed, but captopril did not. The combination of 
captopril and C21 had the same physiologic affect as an ARB. However, the results did not 
coincide with the pathophysiologic changes. 
Angiotensin signaling was initially identified as a system to manage the blood 
pressure in response to different environmental stimuli.  As described in Chapter 1, 
angiotensinogen is converted to angiotensin I by renin which is then converted to the 
ligand AngII by ACE (24). Investigations into AngII signaling were at first primarily focused 
on the renal response to manage blood pressure, but over time research has been 
expanded to identify a role for angiotensin signaling in other systems, such as the heart 
and aorta (50, 51).  
In addition to its function in regulating blood pressure, the renin angiotensin system 
is also known to be involved in triggering inflammation and fibrosis during remodeling of 
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multiple organ systems including the kidneys and the heart. In the kidneys, the renin-
angiotensin-aldosterone-system plays a role in both hypertensive and end-stage kidney 
disease (119). The invasion of fibroblasts and the fibrotic response eventually lead to the 
destruction of nephrons and the interstitium of the kidney, resulting in kidney failure (120). 
In patients, the administration of ARBs has been shown to improve proteinuria, indicating 
improved kidney function and reinforcing the beneficial aspects of ARBs and their 
relationship to fibrosis (121). In the heart, a similar fibrotic response has been observed. It 
has been well established that angiotensin signaling and downstream aldosterone signaling 
have been associated with increased collagen synthesis and deposition (122). They have 
also been associated with degenerative remodeling of the heart, restricted blood flow, and 
heart failure (103). In investigations of these models, data has consistently shown that 
these changes involved TGF-β signaling in the fibrotic response (75). 
5.2 Role of angiotensin signaling in TAAD 
The work presented in this dissertation furthers understanding of the role of 
angiotensin signaling in thoracic aortic remodeling and disease. First, we addressed the role 
of blocking all angiotensin receptors using an ACE inhibitor, captopril.  Previous studies had 
shown another ACE inhibitor, enalapril, was not as effective as losartan in preventing aortic 
growth in the Marfan mouse model (48). Interestingly, in the Fbln4-/- mouse model, 
captopril was as effective as losartan in preventing many of pathologic changes associated 
with the disease such as an increase in vascular area (65). I found that captopril actually 
increased aortic growth in both the aortic root and ascending aorta of the Acta2-/- mouse 
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model and worsened elastin breaks compared with no treatment.  In our TAC model of 
acute hypertension, treatment with captopril did not prevent aortic enlargement and 
vascular inflammation, whereas treatment with losartan did.  These results provide 
additional data to support that ACE inhibitors are not equivalent to ARBs in terms of 
treating thoracic aortic disease. 
In the Acta2-/- mouse model, we identified that the source of increased AngII 
signaling in the aorta was not an increase in ligand. Rather, there was a significantly 
increased sensitivity of the AT1R to endogenous levels of AngII due to ROS increasing NF-κB 
signaling, which drives increased expression of AT1R (11).  It is important to note that the 
Fbn1-/- mice may also have increased AT1R expression since these mice also show 
increased ROS in SMCs and aortic tissues.  
We intended to use the data from the TAC captopril trial to show that TAC-induced 
AT1R signaling in the ascending aorta and aortic root was not dependent on the ligand, 
AngII. Surprisingly, our original captopril trials gave an overwhelmingly poor outcome with 
50% of the mice dying.  Replication of the study by a different surgeon did not demonstrate 
the increased death rates. However, captopril did not rescue the aortic remodeling induced 
by TAC. Markers of vascular inflammation remained elevated in the captopril treated TAC 
mice, and the aortic root and ascending aorta enlarged despite decreased systolic 
pressures in the ascending aorta. These results support our hypothesis that ligand-
independent AT1R signaling is important in driving aortic disease but also raised the 
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question of whether other components of the angiotensin system may play a role in the 
remodeling. 
5.3 Angiotensin signaling through AT1R 
In the past 10 years, angiotensin signaling through AT1R has emerged as a potential 
therapeutic target to prevent thoracic aortic disease.  Initially, losartan was used to block 
canonical TGF-β signaling in the Marfan mouse model.  Additional studies showed that 
losartan could block thoracic aortic disease in multiple mouse models, including our own 
studies of aortic enlargement in the Acta2-/- mice (52, 61). Since blocking TGF-β signaling 
using losartan was so effective in the Marfan mouse model, the use of an ARB as a receptor 
blocker to prevent aortic disease in Marfan patients has been tested in multiple clinical 
trials (123). Many of these trials compared ARB treatment to β-adrenergic blocking agents 
which are considered the gold standard for treatment of aortic disease under the belief 
that it reduces stress on the aorta by reducing left ventricular ejection fraction and heart 
rate (123, 124). These studies focused on aortic growth rates but included other endpoints 
including aortic surgery and acute aortic dissection. 
5.4 Clinical relevance 
At least eight randomized clinical trials of losartan in patients with MFS were 
initiated worldwide. The first prospective trial completed was the Dutch COMPARE trial, 
which assessed 233 MFS patient over the age of 18 years who met diagnostic criteria for 
MFS and were assigned to receive losartan or no additional medications beyond “usual 
therapy”, which commonly included a β-blocker. After a mean follow up of 3.1 years, 
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losartan significantly reduced the rate of aortic root dilation when compared with “usual 
therapy” with the caveat that more patients in the losartan group than in the “usual care” 
group took β-blockers (125). Importantly, a sub study analyzed the 117 MFS patients with 
characterized FBN1 mutations and determined that only individuals with haploinsufficiency 
mutations (n=38, 32.5%), but not individuals with missense mutations (n=79, 67.5%), had a 
reduction in the rate of aortic root dilation with losartan treatment (126). Other outcomes 
beyond rate of aortic root dilation have not been reported for the COMPARE trial.  
The US Pediatric Heart Network Trial was the largest losartan trial (127). It enrolled 
608 patients with MFS between the ages of 6 months and 25 years who met Ghent criteria 
and had significant aortic root enlargement (defined by a Z score > 3.0). The two arms of 
the randomized trial were atenolol (started at 0.5mg/kg/day and increased on the basis of 
hemodynamic response to a maximum of 4mg/kg/ day) and losartan (started at 0.4 
mg/kg/day and increased on the basis of hemodynamic response to a maximum of 1.4 
mg/kg/day). The “mean” dose for young adults was 151 mg atenolol per day and 85 mg of 
losartan per day. The main outcome of the trial did not show any significant difference in 
the rate of aortic root growth between the groups. Similarly, two other double blind clinical 
trials testing losartan against atenolol (128) or against placebo (129) showed no effect of 
losartan in limiting aortic dilatation. In contrast, a small open label pilot study in 28 patients 
with MFS found reduced rate of aortic dilation with losartan added on to β-blockade 
therapy (130). Other clinical studies are still ongoing and results have not been published.  
Although the US Pediatric Heart Network trial was designed to examine rate of 
aortic root growth as the primary outcome and there was no difference between groups, a 
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combined secondary endpoint (death, dissection, aortic root surgery) was reached over the 
3 years clinical trial period in 10 of 268 atenolol-treated patients and in 19 of 267 Losartan-
treated patients. This event rate was almost 2-fold higher in the losartan treated patients, 
but did not reach statistical significance (p value = 0.07). The study was not sufficiently 
powered to examine clinical endpoints of dissection, death, and aortic root surgery, in part 
due to the fact that these events are fortunately very rare in a young cohort like the 
Pediatric Heart Network study. Assuming a similar cohort of MFS patient and the same 
statistical parameters as used for the US Pediatric Heart Network study with an 85% power 
to detect a difference at the level of significance of 0.05, a sample size of 760 patients may 
have reached a statistically significant increase for combined secondary endpoints of 
dissection, aortic surgery, or death in the losartan-treated group. However, this is 
speculative, and extrapolation of the observed event rate in the US Pediatric Heart 
Network trial is uncertain since it occurred exceedingly rarely. But the results from this trial 
raise the important point that future clinical studies cannot focus on aortic dilatation alone, 
and must include clinically important outcomes such as dissection and need for aortic 
surgery. The p-value of 0.07 indicates that there is a 93% chance that the increased 
combined frequency of dissection, death, and aortic root surgery in the losartan-treated 
MFS patients in the US Pediatric Heart Network trial did not occur randomly.  Importantly, 
other smaller clinical trials comparing β-blockade to losartan did not have increased events 
in individuals treated with losartan.  
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5.5 The fibrotic response 
These results bring up an interesting question: is it possible that the fibrotic 
response seen in many of the models may not be detrimental but beneficial? Angiotensin II 
blockade with enalapril was recently reported to reduce the progression of cardiac fibrosis 
in patients with Duchenne and Becker muscle dystrophy in a small randomized clinical trial 
(131, 132). While reduced cardiac or renal fibrosis might improve the functions of these 
organs, it could be of disadvantage for the aorta, where tensile strength is required to 
withstand the force of pulsatile blood flow. Biomechanical studies show that the wall 
increases in thickness to better distribute the hoop stress in response to an increase in 
pulse pressure (25). We also know that AngII signaling drives a fibrotic response in the 
thoracic aorta stimulating fibroblast and myofibroblast proliferation and recruiting 
macrophages and monocytes. Eventually, this leads to adventitial thickening and 
deposition of increased extracellular matrix (28, 30). The thickening of the medial and 
adventitial layer and increased fibrosis with TAC is a physiologic response to increased wall 
stress.  
Hence, blocking aortic fibrosis driven by TGF-β or AngII signaling may not be the 
correct pharmacological target to block aneurysm growth.  This view is supported by 
multiple observations.  First, mutations in genes encoding proteins in the TGF-β canonical 
signaling pathway lead to decreased TGF-β signaling in smooth muscle cells but actually 
cause heritable thoracic aortic disease (8).  It is counter-intuitive to further block TGF-β 
signaling in these individuals to prevent aortic disease.  Second, blocking TGF-β signaling in 
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the MFS mouse model through knockout of the TGF-β type II receptor or knockdown of 
TGF-β2 increases aneurysm formation (133, 134).  Third, blocking TGF-β signaling in 
another mouse model for aortic aneurysms, AngII infusion, increases the penetrance and 
severity of aneurysms and deaths due to aortic rupture (135).  Finally, loss of function 
mutation of lysyl oxidase, an enzyme mediating collagen crosslinking and strongly linked to 
mechanical stability of extracellular matrix and fibrosis, were recently identified as 
causative for familial thoracic aortic aneurysms and dissections (136, 137). Blocking TGF-β 
signaling or blocking proper collagen maturation disrupts the integrity of the thoracic 
aorta.  
AngII signaling also drives fibrosis in the adventitial layer of the thoracic aorta.  
AngII stimulates aortic adventitial fibroblasts to recruit monocytes via secretion of MCP-1, 
and the recruited monocytes further activate the fibroblasts/myofibroblasts to proliferate 
and deposit extracellular matrix, leading to adventitial thickening (28, 105). Although this 
process occurs as part of aneurysm formation associated with AngII infusion, the same 
vascular inflammation and adventitial fibrosis occurs when the forces are increased on the 
aorta by thoracic aortic constriction and this hypertensive remodeling is attenuated by 
losartan (52).  Therefore, aortic adventitial remodeling driven by signaling through the 
AT1R can be physiologic to adapt to increased pressures or pathologic and associated with 
aneurysms.  The unanswered question is whether blocking this adventitial fibrotic 
remodeling through the use of losartan will increase the risk for aortic dissection or 
rupture.    
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5.6 Angiotensin signaling through AT2R 
I asked whether signaling through the AT2R or the Mas receptor might be 
important in TAC-induced aortic remodeling.  Dramatic differences in terms of aortic 
growth and aortic pathology were found when agonists of the AT2R or the Mas receptor 
were used with captopril in TAC mice. The AT2R agonist, C21, in combination with captopril 
was able to prevent aortic enlargement but not vascular inflammation in this model 
system.  Almost the exact opposite was found when the Mas receptor agonist was used – 
aortic enlargement was not rescued but vascular inflammation and much of the associated 
adventitial fibrosis was completely blocked. These results support that additional studies 
must now focus on the use of AT2R agonists as potential therapeutics to help prevent 
thoracic aortic disease.  Although the Mas receptor agonists have shown to be beneficial in 
skeletal and heart diseases, the profound aortic pathologic changes, including collapse of 
the aortic media with SMC loss, and the continued enlargement of the aorta indicate that 
activation of the Mas receptor is not a target for thoracic aortic disease. 
5.7 Study limitations 
Several limitations of my studies should be kept in mind when considering my 
conclusions. First, in many experiments there was insufficient statistical power. 
Furthermore, I did not account for the Bonferroni correction in any of my calculations. This 
may have altered some of the statistical significance in my results. Second, all of my studies 
focused on aneurysm formation but did not effectively investigate the risk for dissections 
and how they relate to the angiotensin system in these models. Ideally, a model that more 
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consistently causes aortic dissection should be utilized for future studies. While some of my 
necropsy studies indicated possible dissections, the frequency of the finding was not 
consistent enough to draw conclusions. Our lab is currently attempting to define better 
mouse models for aortic dissection. Once those models are established, one of the first 
goals should be to assess whether changes in the fibrotic or inflammatory responses 
associated with the angiotensin pathway may hinder or exacerbate dissection.  
5.8 Future directions 
Moving forward, we should pay closer attention to the difference between the 
ascending aorta and the aortic root. We know that they are derived from distinct 
developmental origins (3), but how does that specifically affect their different responses to 
the same stimulus? Recent results have also indicated an inducible nitric oxide synthase 
was potential therapeutic target (88), and it would be interesting to determine how the 
AT2R or Mas could play a role in this system. Finally, I would also be interested in going 
back and to address my original question about which intracellular pathway downstream of 
the AT1R is activated in the ascending aorta in response to biomechanical stress.   
My goal at the start of this project was to identify pathways that might improve the 
treatment of thoracic aortic aneurysms. I believe that the results of my studies contribute, 
in a small way, to our understanding of therapeutic strategies targeting the angiotensin 
system. While ARBs are considered the therapeutic with the highest potential of all the 
pharmaceutical manipulations of the angiotensin system, the angiotensin system is far 
more complicated and dynamic than most would have ever anticipated. Much more time 
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needs to be invested in our understanding of the angiotensin system in thoracic aortic 
disease, and we should not assume that blocking particular receptors or pathways in other 
systems, such as the kidneys or heart, will also be beneficial in the thoracic aorta. We must 
carefully choose our experimental designs to better investigate disease pathologies and 
possible therapeutic strategies.  
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